,PageNo,Text
0,page_0,"CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ Page 1 of Ï²Ï´ Gene Therapy for Achromatopsia Í¾ CNGAÏ¯Í¿ An open label, multiÍ²centre, Phase IÍ¬II dose escalation trial of a recombinant adenoÍ²associated virus vector Í¾AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯Í¿ for gene therapy of children with Achromatopsia owing to defects in CNGAÏ¯ Version Version Ï².Ï¬ Date Ï­Ï²AprÏ®Ï¬Ï®Ï­ Sponsor MeiraGTx UK II Ltd. Sponsorâ€™s Protocol Number MGTÏ¬ Ï­Ï® Trial registration EudraCT Ï®Ï¬Ï­Ï´ Í²Ï¬Ï¬Ï¯Ï°Ï¯Ï­ Í²Ï®Ïµ Authorisation: Chief Investigator Name Role Professor of Retinal Studies UCL Institute of Ophthalmology Signature Date Authorisation: Sponsor Representative Name Role MeiraGTx Chief Medical Officer Signature Date  "
1,page_1,CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï±.Ï¬ Ï¬ÏµJulÏ®Ï¬Ï®Ï¬ Page 2 of Ï²Ï´ TabÂe Â‘f CÂ‘ÂÂ–eÂÂ–Â• 1 Administrative information ................................................................................................... Ï³ 1.1 Compliance ................................................................................................................... Ï³ 1.2 Sponsor ........................................................................................................................ Ï´ 1.3 Structured trial summary ............................................................................................... Ïµ 1.Ï° Roles and responsibilities ............................................................................................ 11 2 Trial Diagram ...................................................................................................................... 12 3 Abbreviations ..................................................................................................................... 13 Ï° Introduction ....................................................................................................................... 1Ï± Ï°.1 Background and Rationale ........................................................................................... 1Ï± Ï°.1.1 Background ......................................................................................................... 1Ï± Ï°.1.2 Pre-clinical data ................................................................................................... 1Ï± Ï°.1.3 Clinical data ......................................................................................................... 1Ï² Ï°.1.Ï° Rationale ............................................................................................................. 1Ï³ Ï°.1.Ï± Assessment and management of risk .................................................................... 1Ï³ Ï°.1.Ï±.1 Risk of immune responses to AAVÏ´-hG1.Ï³p.coCNGA3 ....................................... 1Ï´ Ï°.1.Ï±.2 Risk of vector transmission to other organs ...................................................... 1Ï´ Ï°.1.Ï±.3 Risks of insertional mutagenesis and oncogenesis ............................................ 1Ïµ Ï°.1.Ï±.Ï° Risk of germline transmission .......................................................................... 1Ïµ Ï°.1.Ï±.Ï± Risk of surgical adverse effects ........................................................................ 1Ïµ Ï°.1.Ï±.Ï² Risk of adverse effects of corticosteroids ......................................................... 20 Ï°.1.Ï±.Ï³ Risks of investigations performed during assessment and follow up ................. 21 Ï°.1.Ï±.Ï´ Risk of rod photoreceptor dysfunction ............................................................. 21 Ï°.1.Ï±.Ïµ Risk of thinning of the fovea ............................................................................ 21 Ï°.1.Ï±.10 Risk of visual imbalance ................................................................................ 21 Ï°.1.Ï±.11 Conclusion on the risk-benefit ratio .............................................................. 22 Ï°.1.Ï² Explanation for Choice of Comparators ................................................................. 22 Ï°.2 Objectives ................................................................................................................... 22 Ï°.2.1 Primary Objective ................................................................................................ 22 Ï°.2.2 Secondary Objective ............................................................................................ 22 Ï°.3 Trial Design ................................................................................................................. 22 Ï°.3.1.1 Separate longer term follow up study .................................................................. 23
2,page_2,CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï±.Ï¬ Ï¬ÏµJulÏ®Ï¬Ï®Ï¬ Page 3 of Ï²Ï´ Ï°.3.2 IMP administration Review and Dose Escalation Criteria and Process .................... 2Ï° Ï°.3.2.1 Dose escalation criteria and Dose Limiting Events ............................................ 2Ï° Ï°.3.2.2 Dosing process ................................................................................................. 2Ï° Ï°.3.2.2.1 Cohort 1 ........................................................................................................ 2Ï° Ï°.3.2.2.2 Cohort 2 ........................................................................................................ 2Ï± Ï°.3.2.2.3 Cohort 3 ........................................................................................................ 2Ï± Ï°.3.2.2.2.Ï° Adult Cohort-United States ......................................................................... 2Ï± Ï°.3.2.2.Ï± Additional considerations .............................................................................. 2Ï± Ï± Methods............................................................................................................................. 2Ï² Ï±.1 Site Selection .............................................................................................................. 2Ï² Ï±.1.1 Study Setting ....................................................................................................... 2Ï² Ï±.1.2 Site/Investigator Eligibility Criteria ....................................................................... 2Ï² Ï±.1.2.1 Principal Investigatorâ€™s (PI) Qualifications and Agreements ............................... 2Ï³ Ï±.1.2.2 Resourcing at site ............................................................................................. 2Ï³ Ï±.2 Site approval and activation ........................................................................................ 2Ï³ Ï±.3 Participants ................................................................................................................. 2Ï´ Ï±.3.1 Eligibility Criteria.................................................................................................. 2Ï´ Ï±.3.1.1 Participant selection ......................................................................................... 2Ï´ Ï±.3.1.2 Participant Inclusion Criteria ............................................................................. 2Ï´ Ï±.3.1.3 Participant Exclusion Criteria ............................................................................ 2Ïµ Ï±.3.1.Ï° Eligibility Criteria for Individuals Performing the Interventions .......................... 30 Ï±.3.1.Ï± Co-enrolment Guidance .................................................................................... 30 Ï±.3.1.Ï² Screening Procedures ....................................................................................... 30 Ï±.3.1.Ï².1 Informed Consent Procedure ..................................................................... 30 Ï±.3.1.Ï².2 Screening Period ........................................................................................ 31 Ï±.3.1.Ï².3 Enrolment .................................................................................................. 32 Ï±.Ï° Intervention ................................................................................................................ 32 Ï±.Ï°.1 Name and Description of Investigational Medicinal Product .................................. 32 Ï±.Ï°.1.1 ATIMPs Classified as Genetically Modified Organisms ....................................... 33 Ï±.Ï°.1.2 Source of ATIMPs ............................................................................................. 33 Ï±.Ï°.1.3 Preparation and Labelling of the Investigational Medicinal Product ................... 33 Ï±.Ï°.1.Ï° Description and Justification of Route of Administration and Dose .................... 33 Ï±.Ï°.1.Ï± Name and Description of Each Non-Investigational Medicinal Drug (NIMP)........ 3Ï°
3,page_3,CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï±.Ï¬ Ï¬ÏµJulÏ®Ï¬Ï®Ï¬ Page Ï° of Ï²Ï´ Ï±.Ï°.2 Protocol defined clinical schedule ......................................................................... 3Ï± Ï±.Ï°.2.1 Baseline Assessments ....................................................................................... 3Ï± Ï±.Ï°.2.2 ATIMP administration Procedures .................................................................... 3Ï³ Ï±.Ï°.2.2.1 Pre-operative Procedures ........................................................................... 3Ï³ Ï±.Ï°.2.2.2 Technique for intraocular administration of ATIMP ..................................... 3Ï´ Ï±.Ï°.2.3 Subsequent Assessments .................................................................................. 3Ï´ Ï±.Ï°.2.Ï° Laboratory Procedures ..................................................................................... Ï°0 Ï±.Ï°.3 Dispensing ........................................................................................................... Ï°1 Ï±.Ï°.3.1 Receipt and Storage of the Advanced Therapy Investigational Medicinal Product .. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ï° 1 Ï±.Ï°.Ï° Dosages ............................................................................................................... Ï°1 Ï±.Ï°.Ï°.1 Dosages and dosage modifications ................................................................... Ï°1 Ï±.Ï°.Ï± Accountability ...................................................................................................... Ï°2 Ï±.Ï°.Ï² Compliance and Adherence .................................................................................. Ï°2 Ï±.Ï°.Ï³ Concomitant Care ................................................................................................ Ï°2 Ï±.Ï°.Ï´ Overdose of Trial Medication ............................................................................... Ï°2 Ï±.Ï°.Ïµ Protocol Discontinuation ...................................................................................... Ï°2 Ï±.Ï°.Ïµ.1 Participant Withdrawal .................................................................................... Ï°2 Ï±.Ï°.Ïµ.2 Trial Stopping Rules .......................................................................................... Ï°3 Ï±.Ï± Outcomes ................................................................................................................... Ï°3 Ï±.Ï±.1 Primary Outcomes ............................................................................................... Ï°3 Ï±.Ï±.2 Secondary Outcomes ........................................................................................... Ï°Ï° Ï±.Ï² Trial Assessments ........................................................................................................ Ï°Ï± Ï±.Ï².1 Early Stopping of Follow-up .................................................................................. Ï°Ï³ Ï±.Ï².2 Loss to Follow-up ................................................................................................. Ï°Ï³ Ï±.Ï².3 Trial Closure ......................................................................................................... Ï°Ï³ Ï±.Ï².Ï° Long Term Follow-Up After the End of the Trial .................................................... Ï°Ï³ Ï±.Ï³ Sample Size ................................................................................................................. Ï°Ï³ Ï±.Ï´ Recruitment and Retention ......................................................................................... Ï°Ï³ Ï±.Ï´.1 Recruitment ......................................................................................................... Ï°Ï³ Ï±.Ï´.2 Retention ............................................................................................................ Ï°Ï³ Ï±.Ïµ Assignment of Intervention ......................................................................................... Ï°Ï´ Ï±.Ïµ.1 Allocation ............................................................................................................ Ï°Ï´
4,page_4,"CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï±.Ï¬ Ï¬ÏµJulÏ®Ï¬Ï®Ï¬ Page Ï± of Ï²Ï´ Ï±.10 Data Collection, Management and Analysis.................................................................. Ï°Ï´ Ï±.10.1 Data collection, management and entry ............................................................... Ï°Ï´ Ï±.10.2 Non-Adherence and Non-Retention ...................................................................... Ï°Ïµ Ï±.10.3 Statistical Methods .............................................................................................. Ï°Ïµ Ï±.10.3.1 Statistical Analysis Plan ................................................................................. Ï°Ïµ Ï±.10.3.2 Statistical Methods â€“ Primary Outcome Analysis ........................................... Ï°Ïµ Ï±.10.3.3 Statistical Methods â€“ Secondary Outcome Analysis ....................................... Ï°Ïµ Ï±.10.3.Ï° Statistical Methods â€“ Health Economics Analysis ........................................... Ï±0 Ï±.11 Data Monitoring .......................................................................................................... Ï±0 Ï±.11.1 Safety Data Monitoring Committee ..................................................................... Ï±0 Ï±.11.2 Interim Analyses .................................................................................................. Ï±0 Ï±.11.3 Data Monitoring for Harm .................................................................................... Ï±0 Ï±.11.3.1 Safety reporting ............................................................................................ Ï±0 Ï±.11.3.2 Other Notifiable Adverse Events ................................................................... Ï±2 Ï±.11.3.3 Procedures to follow in the event of female participants becoming pregnant . Ï±2 Ï±.11.3.Ï° Procedures to follow in the event of the partners of male participants becoming pregnant .................................................................................................................... Ï±2 Ï±.11.3.Ï± Investigator responsibilities relating to safety reporting ................................ Ï±3 Ï±.11.3.Ï±.1 Seriousness assessment ............................................................................ Ï±3 Ï±.11.3.Ï±.2 Severity or grading of Adverse Events ....................................................... Ï±3 Ï±.11.3.Ï±.3 Causality .................................................................................................. Ï±Ï° Ï±.11.3.Ï±.Ï° Expectedness ........................................................................................... Ï±Ï° Ï±.11.3.Ï² Notifications ................................................................................................. Ï±Ï² Ï±.11.3.Ï².1 Notifications by the Investigator to Pharmacovigilance ............................. Ï±Ï² Ï±.11.3.Ï².2 Reporting Urgent Safety Measures ........................................................... Ï±Ï² Ï±.11.3.Ï².3 PV Service Provider responsibilities .......................................................... Ï±Ï³ Ï±.11.3.Ï².Ï° Reporting SUSARs in International Trials .................................................. Ï±Ï³ Ï±.11.3.Ï².Ï± Annual Progress Reports ........................................................................... Ï±Ï³ Ï±.11.Ï° Quality Assurance and Control ............................................................................. Ï±Ï³ Ï±.11.Ï°.1 Risk Assessment ........................................................................................... Ï±Ï³ Ï±.11.Ï°.2 Clinical Monitoring ....................................................................................... Ï±Ï³ Ï±.11.Ï°.3 Direct access to participant records ............................................................. Ï±Ï³ Ï±.11.Ï°.Ï° Trial Oversight .............................................................................................. Ï±Ï³"
5,page_5,CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï±.Ï¬ Ï¬ÏµJulÏ®Ï¬Ï®Ï¬ Page Ï² of Ï²Ï´ Ï±.11.Ï°.Ï°.1 Clinical Management Team ....................................................................... Ï±Ï´ Ï±.11.Ï°.Ï°.2 Safety Data Monitoring Committee........................................................... Ï±Ï´ Ï².1 Research Ethics Approval ............................................................................................. Ï±Ï´ Ï².2 Regulatory Authority Approvals ................................................................................... Ï±Ï´ Ï².3 Other approvals ......................................................................................................... Ï±Ïµ Ï².Ï° Protocol Amendments ................................................................................................. Ï±Ïµ Ï².Ï± Consent or Assent ....................................................................................................... Ï±Ïµ Ï².Ï² Confidentiality ............................................................................................................ Ï²0 Ï².Ï³ Declaration of Interests ............................................................................................... Ï²1 Ï².Ï´ Indemnity ................................................................................................................... Ï²1 Ï².Ïµ Finance ....................................................................................................................... Ï²1 Ï².10 Archiving ..................................................................................................................... Ï²1 Ï².10.1 Archiving of Essential Trial Documentation ........................................................... Ï²1 Ï².11 Access to Data ............................................................................................................. Ï²2 Ï².12 Ancillary and Post-trial Care ........................................................................................ Ï²2 Ï².13 Publication Policy ........................................................................................................ Ï²2 Ï².13.1 Trial Results ......................................................................................................... Ï²2 Ï³ Ancillary Studies ................................................................................................................. Ï²3 Ï´ Appendix: Guidance on Study Conduct during the COVID-1Ïµ Pandemic ................................ Ï²3 Ïµ Protocol Amendments ....................................................................................................... Ï²Ï² 10 References ...................................................................................................................... Ï²Ï³
6,page_6,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ Page Ï³ of Ï²Ï´ Í³ AdÂiÂiÂ•Â–Â”aÂ–iÂ˜e iÂfÂ‘Â”ÂaÂ–iÂ‘Â This document describes the Gene Therapy for Achromatopsia Í¾CNGAÏ¯Í¿ trial, sponsored and coÍ²ordinated by MeiraGTx UK II Ltd. In early Ï®Ï¬Ï­Ïµ, MeiraGTx UK II Ltd. Í¾MeiraGTxÍ¿ entered into a worldwide collaboration and license agreement with Janssen Research and Development, LLC Í¾JRDÍ¿, which is based in the US. The partnership seeks to develop, manufacture, and commercialize gene therapy treatments for inherited retinal diseases Í¾IRDsÍ¿. MeiraGTx and JRD are collaborating on the development of AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ formerly known as AAVÏ®Í¬Ï´Í²hGÏ­.Ï³p.coCNGAÏ¯. It provides information about procedures for entering participants into the trial, and provides sufficient detail to enable: an understanding of the background, rationale, objectives, trial population, intervention, methods, statistical analyses, ethical considerations, dissemination plans and administration of the trial; replication of key aspects of trial methods and conduct; and appraisal of the trialâ€™s scientific and ethical rigour from the time of ethics approval through to dissemination of the results. The protocol should not be used as an aideÍ²memoire or guide for the treatment of other patients. Every care has been taken in drafting this protocol, but corrections or amendments may be necessary. These will be circulated to registered investigators in the trial. Sites entering participants for the first time should confirm they have the correct version through a member of the trial team at MeiraGTx UK II Ltd. MeiraGTx UK II Ltd. supports the commitment that its trials adhere to the SPIRIT guidelines. As such, the protocol template is based on an adaptation of the Standard Protocol Items: Recommendations for Interventional Trials Í¾SPIRITÍ¿ Ï®Ï¬Ï­Ï® Statement for protocols of clinical trials Í¾Chan et AlÍ˜ Ï®Ï¬Ï­Ï¯aÍ¿. The SPIRIT Statement Explanation and Elaboration document Í¾Chan et AlÍ˜ Ï®Ï¬Ï­Ï¯bÍ¿ can be referred to, or a member of the MeiraGTx UK II Ltd. Clinical Operations team can be contacted for further detail about specific items. Í³Ç¤Í³ CÂ‘ÂÂ’ÂiaÂce The trial will be conducted in compliance with the approved protocol, the Declaration of Helsinki Í¾Ï®Ï¬Ï¬Ï´Í¿, the principles of Good Clinical Practice Í¾GCPÍ¿ as laid down by the Commission Directive Ï®Ï¬Ï¬Ï±Í¬Ï®Ï´Í¬EC with implementation in national legislation in the UK by Statutory Instrument Ï®Ï¬Ï¬Ï²Í¬Ï­ÏµÏ®Ï´ and subsequent amendments, Advanced Therapy Medicinal Products Í¾ATMPÍ¿ Regulations Í¾ECÍ¿ No Ï­Ï¯ÏµÏ°Í¬Ï®Ï¬Ï¬Ï³, the Human Tissue Í¾Quality and Safety for Human ApplicationÍ¿ Regulations Ï®Ï¬Ï¬Ï³, the General Data Protection Regulations Ï®Ï¬Ï­Ï²Í¬Ï²Ï³Ïµ, and the National Health Service Í¾NHSÍ¿ Research Governance Framework for Health and Social Care Í¾RGFÍ¿. US sites will comply with Ï®Ï­ CFR Ï¯Ï­Ï® in the Code of Federal Regulations, and the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules Í¾November Ï®Ï¬Ï­Ï¯Í¿. The participating sites will inform MeiraGTx UK II Ltd. as soon as they are aware of a possible serious breach of compliance, so that MeiraGTx UK II Ltd. can fulfil its requirement to report the breach if necessary, within the relevant applicable timelines specified in each country in which the study is being conducted. For the purposes of reporting, a â€˜serious breachâ€™ is one that is likely to affect to a significant degree: x The safety or physical or mental integrity of the participants in the trial, or x The scientific value of the trial."
7,page_7,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ Page Ï´ of Ï²Ï´ Í³Ç¤Í´ SÂ’Â‘ÂÂ•Â‘Â” MeiraGTx UK II Ltd., ÏµÏ® Britannia Walk, London NÏ­ Ï³NQ, is the study sponsor."
8,page_8,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ Page Ïµ of Ï²Ï´ Í³Ç¤Íµ SÂ–Â”Â—cÂ–Â—Â”ed Â–Â”iaÂ Â•Â—ÂÂaÂ”Â› Primary Registry and Trial Identifying Number EudraCT Ï®Ï¬Ï­Ï´Í²Ï¬Ï¬Ï¯Ï°Ï¯Ï­Í²Ï®Ïµ Secondary Identifying Numbers MeiraGTx UK II Ltd. registration number: MGTÏ¬Ï­Ï® Source of Monetary or Material Support MeiraGTx UK II Ltd. Sponsor MeiraGTx UK II Ltd. Contact for Public Queries ocularinfoÎ›meiragtx.com Contact for Scientific Queries Chief Medical Officer Í¾MeiraGTxÍ¿ Ï°Ï±Ï¬ East Ï®Ïµth Street Ï­Ï°th Floor New York, NY Ï­Ï¬Ï¬Ï­Ï² Tel : Ï²Ï°Ï²Í²Ï´Ï²ÏµÍ²Ï³Ï¯Ï³Ïµ Email : Public Title Gene Therapy for Achromatopsia Í¾ CNGAÏ¯ Í¿ Scientific Title An open label, multiÍ²centre, Phase IÍ¬II dose escalation trial of an adenoÍ²associated virus vector Í¾AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯Í¿ for gene therapy of children with Achromatopsia owing to defects in CNGAÏ¯ Countries of Recruitment United Kingdom, United States of America Health Condition Achromatopsia InterventionÍ¾sÍ¿ Open label, nonÍ²randomised, doseÍ²escalation Phase IÍ¬II doseÍ²escalation study, by subretinal administration of AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ in up to Ï­Ï´ paediatric participants with Achromatopsia owing to mutations in the CNGAÏ¯ gene. Key Inclusion and Exclusion Criteria Key Inclusion Criteria: x Aged Ï¯ to Ï­Ï± years old x Achromatopsia caused by mutations in CNGAÏ¯ x Evidence of relative preservation of photoreceptors at the macula x Able to undertake ageÍ²appropriate clinical assessments x Willing to give consent for the use of blood and blood components collected throughout the trial for the investigation of immune response to Advanced Therapy Investigational Product Í¾ATIMPÍ¿. Key Exclusion Criteria: x Female adolescents who are pregnant or breastfeeding x IntraÍ²ocular surgery within Ïµ months of screening x Ocular or systemic disorder that may preclude subretinal surgery andÍ¬or interfere with interpretation of the study results."
9,page_9,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 10 of Ï²Ï´ x Participated in another research study involving an investigational therapy for ocular disease within the last Ï² months x Use of high dose regular nonÍ²steroidal antiÍ²inflammatory drugs at the time of screening x Have any other condition that the Principal Investigator Í¾PIÍ¿ considers makes them inappropriate for entry into the trial x Are unwilling to consider the possibility of entry into a subsequent longer term follow up study x During the Ï² weeks prior to baseline, have had any confirmed SARSÍ²CoVÍ²Ï® Í¾COVIDÍ²Ï­ÏµÍ¿ infection Study Type Phase IÍ¬II, openÍ²label, nonÍ²randomised, multiÍ²centre, dose escalation study, followed by dose confirmation in children with Achromatopsia owing to defects in CNGAÏ¯ Date of First Enrolment Anticipated QÏ­ Ï®Ï¬Ï­Ïµ Target Sample Size Up to Ï­Ï´ participants Primary OutcomeÍ¾sÍ¿ The primary outcome is safety of subretinal administration of AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯. Safety is defined as the absence of ATIMPÍ²related: x Reduction in visual acuity by Ï­Ï± ETDRS letters or more that fails to resolve to within Ï­Ï± letters of baseline in a Ï°Í²week period once prophylactic treatment commences x Severe unresponsive inflammation x Infective endophthalmitis x Ocular malignancy x Grade III or above nonÍ²ocular SUSAR Safety will be assessed for Ï² months after the intervention in this study, and a further optional Ï°.Ï± years in a separate subsequent study. Key Secondary Outcomes The secondary outcomes are measures of the efficacy of the intervention, which will be performed on an individual participant basis and will be descriptive in nature. Efficacy will be assessed at several time points between Ï¯ to Ï² months after the intervention: Ï­Í¿ Any improvement in visual function from baseline that is greater than the baseline variation for that test and is sustained for at least two consecutive assessments. Ï®Í¿ Any improvement in retinal function from preÍ²intervention that is greater than the baseline variation and measurable by electroretinography Í¾ERGÍ¿. Ï¯Í¿ Quality of life measures including EQÍ²Ï±D and IVI or equivalent as appropriate."
10,page_10,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 11 of Ï²Ï´ Í³Ç¤Í¶ RÂ‘ÂeÂ• aÂd Â”eÂ•Â’Â‘ÂÂ•ibiÂiÂ–ieÂ• Agreements that include detailed roles and responsibilities will be in place between participating sites and MeiraGTx UK II Ltd. These membership lists are correct at the time of writing; please see terms of reference documentation in the TMF for current lists. Name Affiliation Role and responsibilities University College London Chief Investigator, Moorfieldâ€™s Eye Hospital University College London Co Í´ Investigator, Moorfieldsâ€™s Eye Hospital University College London Senior Scientist MeiraGTx UK II Ltd. Chief Medical Officer MeiraGTx UK II Ltd. Chief Development Officer MeiraGTx UK II Ltd. Senior Director Clinical Operations MeiraGTx UK II Ltd. Clinical Project Manager"
11,page_11,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 12 of Ï²Ï´ Í´ TÂ”iaÂ DiagÂ”aÂ Children with cone dysfuction syndrome consistent with CNGAÏ¯deficiency Genetic screening for CNGAÏ¯by accredited laboratory Í¾before or after consentÍ¿ ParticipantÍ¬parentÍ¬guardian Í¾and childÍ¿ given participant information sheet and asked to provide informed consentÍ¬assent ScreeningÍ¬baseline tests Í¾genetic testing, health status, physical examination, vital signs, ocular examination, visual acuity, OCT, Full Field Stimulus electrophysiology, pregnancy Oral Steriods prescribed Ï­ week BEFORE Surgery ATIMP administration surgery Í¾Ï­ of Ï¯ dosesÍ¿Pregnancy test if applicable Ï­ day postÍ²operative follow up Ï¯ days postÍ²operative follow up Ï­ week postÍ²operative follow up Ï® weeks postÍ²operative follow up Ï° weeks postÍ²operative follow up Ï² weeks postÍ²operative follow up Ï¯ months postÍ²operative follow up Ï² months postÍ²operative follow up Recruitment to LongÍ²term Follow Up StudyClinical assessments during follow up period including ocular exam, labs Î˜ visual assessments Antibiotic Î˜ corticosteroid prescribed Ï­Í²Ï° weeks postÍ²surgery IneligibleÍ¬ unwilling to consent"
12,page_12,Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 13 of Ï²Ï´ Íµ AbbÂ”eÂ˜iaÂ–iÂ‘ÂÂ• AAV AdenoÍ²Associated Virus Ad Adenovirus AE Adverse Event AF Autofluorescence AO Adaptive Optics AR Adverse Reaction ATIMP Advanced Therapy Investigational Medicinal Product ATMP Advanced Therapy Medicinal Products Bd Bis die twice daily BIOM Binocular Indirect Ophthalmo Microscope CA Competent Authority cDNA complementary Deoxyribonucleic Acid CEO Chief Executive Officer cGMP cyclic guanosine monophosphate CI Chief Investigator CMT Clinical Management Team CNGAÏ¯ Cyclic NucleotideÍ²Gated cation channel BetaÍ²Ï¯ CRF Case Report Form CRO Contract Research Organization CTA Clinical Trial Authorisation CTIMP Clinical Trial of Investigational Medicinal Product DLE DoseÍ²limiting event DNA Deoxyribonucleic acid DSUR Development Safety Update Report ELISA EnzymeÍ²linked Immunosorbent Assay ELISPOT EnzymeÍ²linked ImmunoSpot Assay EMA European Medicines Agency ERG Electroretinography ETDRS Early Treatment Diabetic Retinopathy Study EU European Union EUCTD European Clinical Trials Directive EudraCT European Clinical Trials Database EudraVIGILANCE European database for Pharmacovigilance FAF Fundus Autofluorescence FDA Í¾USÍ¿ Food and Drug Administration FWA Federal Wide Assurance GCP Good Clinical Practice GLP Good Laboratory Practice GMO Genetically Modified Organism GMP Good Manufacturing Practice GMSC Genetic Modification Safety Committee GTAC Gene Therapy Advisory Committee hCAR Human Cone Arrestin HIPAA Health Insurance Portability and Accountability Act HRA Health Research Authority HSE Health and Safety Executive IB Investigator Brochure ICF Informed Consent Form ICH International Conference on Harmonisation ISe Inner Segment Ellipsoid SDMC Safety andData Monitoring Committee IMP Investigational Medicinal Product IMPD Investigational Medicinal Product Dossier IND Investigational New Drug IRB Institutional Review Board ISCEV International Society for Clinical Electrophysiology of Vision KEC Kellogg Eye Centre LCA Leber congenital amaurosis MHRA Medicines and Healthcare products Regulatory Agency
13,page_13,Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ï° of Ï²Ï´ mL Millilitre ms Millisecond mRNA Messenger RNA MTD Maximum Tolerated Dose NHS National Health Service NIH National Institutes of Health NIMP NonÍ²Investigational Medicinal Product OBA Office of Biotechnology Activities OCT Optical Coherence Tomography PCR Polymerase Chain Reaction PERG Pattern Electroretinogram PHI Protected Health Information PI Principal Investigator PIS Participant Information Sheet QA Quality Assurance QALY Quality Adjusted Life Year QC Quality Control qds quarter die sumendus Í¾four times dailyÍ¿ QOL Quality of Life QP Qualified Person for release of ATIMP rAAV Recombinant adeno associated virus REC Research Ethics Committee RG Research grade RGF Research Governance Framework RNA Ribonucleic acid RPE Retinal Pigment Epithelium SAE Serious Adverse Event SAP Statistical Analysis Plan SAR Serious Adverse Reaction SDÍ²OCT Spectral Domain Optical Coherence Tomography SOP Standard Operating Procedure SSA Site Specific Approval SSAR Suspected Serious Adverse Reaction SUSAR Suspected Unexpected Serious Adverse Reaction SVÏ°Ï¬ Simian virus Ï°Ï¬ TMF Trial Master File tRNA Transfer ribonucleic acid UAR Unexpected Adverse Reaction UCL University College London UK United Kingdom of Great Britain Î˜ Northern Ireland US United States vg Viral Genomes WGTU Wolfson Gene Therapy Unit WT Wild type
14,page_14,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ï± of Ï²Ï´ Í¶ IÂÂ–Â”Â‘dÂ—cÂ–iÂ‘Â Í¶Ç¤Í³ BackgÂ”Â‘Â—Âd aÂd RaÂ–iÂ‘ÂaÂe Í¶Ç¤Í³Ç¤Í³ BackgÂ”Â‘Â—Âd Achromatopsia is a hereditary autosomal recessive condition characterized by intact rod function and absent cone function. As a consequence of loss of cone function in the retina, Achromatopsia patients present with reduced or complete loss of colour vision, reduced visual acuity, involuntary backÍ²andÍ²forth eye movements Í¾pendular nystagmusÍ¿, a disabling increase in sensitivity to light Í¾photophobiaÍ¿, and a central scotoma Í¾Kohl et alÍ˜, Ï®Ï¬Ï­Ï¯; Aboshiha et alÍ˜, Ï®Ï¬Ï­Ï²; Michaelides et alÍ˜, Ï®Ï¬Ï¬Ï°Í¿. In the United States, ACHM is estimated to affect approx. Ïµ,Ï³Ï¬Ï¬ individuals Í¾Judd, Ï­ÏµÏ°Ï¯; Sharpe et alÍ˜, Ï­ÏµÏµÏ¬; Sharpe et alÍ˜, Ï­ÏµÏµÏµÍ¿, in Ï®Ï±Ğ¹Í²Ï¯Ï±Ğ¹ of whom the condition results from mutations in the CNGAÏ¯ gene Í¾Kohl et alÍ˜, Ï®Ï¬Ï¬Ï±; Aboshiha et alÍ˜, Ï®Ï¬Ï­Ï²Í¿; similarly, it is estimated that approximately Ï°,Ï¬Ï¬Ï¬ people are affected in the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aO., 2007, NDWNXQDUDMDK HW aO., 2007). CRPSDULVRQ RI PXOWLSOH AAV VHURW\SHV DIWHU VXEUHWLQDO LQMHFWLRQ LQ WKH H\HV RI QRQ-KXPDQ SULPDWHV (NHPV) VKRZHG AAV2/8 WR EH DPRQJ WKH PRVW HIILFLHQW YHFWRUV IRU JHQH WUDQVIHU WR WKH SULPDWH FRQHV (VDQGHQEHUJKH HW aO., 2013, VDQGHQEHUJKH HW aO., 2011). Achromatopsia resulting from mutations in CNGAÏ¯ has several characteristics that make it an appropriate candidate disease to demonstrate proofÍ²ofÍ²principle in a firstÍ²inÍ²man trial of gene therapy for photoreceptor disease. Effective improvement in cone photoreceptor function, which is otherwise absent Í¾or markedly reducedÍ¿ in this condition, would provide a clear, rapid and reliable measure of outcome. In addition, Achromatopsia is largely nonÍ²progressive and the extended survival of cones, despite their profound lack of function, presents a wide window of opportunity during which gene supplementation could lead to significant benefit in coneÍ²mediated vision. Although younger children may benefit most from gene supplementation therapy by virtue of their greater visual plasticity, we anticipate that the intervention may offer benefit across a range of ages and we aim to define this range. For this reason, participants of a range of ages will be included. Í¶Ç¤Í³Ç¤Í´ PÂ”eÇ¦cÂiÂicaÂ daÂ–a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
15,page_15,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ï² of Ï²Ï´ IQ D IXUWKHU XQSXEOLVKHG VWXG\, DGPLQLVWUDWLRQ RI AAV8-KG1.7S.FRCNGA3 ZDV DVVRFLDWHG ZLWK D PDUNHG LQFUHDVH LQ FRQH-FHOO VXUYLYDO DQG V\QDSWLF LQWHJULW\ LQ WUHDWHG H\HV ZKHQ FRPSDUHG WR XQWUHDWHG H\HV DW 11 PRQWKV. TKLV VWXG\ FRQVWLWXWHV RQH RI WKH PRVW HIIHFWLYH UHVFXHV RI DQ DQLPDO PRGHO RI D SKRWRUHFHSWRU GHIHFW UHSRUWHG WR GDWH, VXJJHVWLQJ WKDW WKLV GHIHFW PD\ EH SDUWLFXODUO\ DPHQDEOH WR JHQH VXSSOHPHQWDWLRQ WKHUDS\. The efficacy and safety of AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ is also the subject of an ongoing Ï´Í²week toxicology and biodistribution rodent study and ongoing Ï²Í²month long term gross and ocular toxicity rodent study. In addition, a series of nonclinical pharmacology and toxicologyÍ¬biodistribution studies have been conducted with a closely related vector Í¾AAVÏ®Í¬Ï´Í²hCARp.hCNGBÏ¯Í¿ containing the human CNGBÏ¯ gene. As this vector is comprised of the same vector backbone and capsid Í¾serotype Ï´Í¿ as AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ Í¾albeit with a different promoter and transgeneÍ¿, these data are considered relevant, supportive and representative of the nonclinical programme for AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯. Í¶Ç¤Í³Ç¤Íµ CÂiÂicaÂ daÂ–a No clinical studies using AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ have been conducted to date in any country. However, proofÍ²ofÍ²principle for gene replacement therapy in the retina has been demonstrated using recombinant adenoÍ²associated virus serotype Ï® Í¾rAAVÏ®Í¬Ï®Í¿ vectors delivering the retinal pigment epitheliumÍ²specific protein Ï²Ï± Í¾ RPEÏ²Ï± Í¿ gene in several completed clinical trials in Leber Congenital Amaurosis Í¾LCAÏ®Í¿ patients Í¾ Bainbridge et al ., Ï®Ï¬Ï¬Ï´ ; Maguire et al ., Ï®Ï¬Ï¬Ï´ ; Cideciyan et al ., Ï®Ï¬Ï¬Ïµ ; Russell et alÍ˜ , Ï®Ï¬Ï­Ï± ; Russell et alÍ˜ , Ï®Ï¬Ï­Ï³ Í¿. In these studies, adults and children as young as Ï² years of age were administered AAV vectors by subretinal administration, using analogous methods Í¾but with differing doses and volumesÍ¿ to those proposed for the planned clinical study, at viral doses ranging from Ï­.Ï± x Ï­Ï¬ Ï­Ï¬ vgÍ¬eye to Ï­ x Ï­Ï¬Ï­Ï® vgÍ¬eye, with injection volumes ranging from Ï¬.Ï­Ï± to Ï­ mL. In one of these clinical studies the vector was delivered by subretinal administration that in many cases encompassed the fovea Í¾ Bainbridge et al ., Ï®Ï¬Ï¬Ï´ Í¿. This protocol describes MeiraGTxâ€™s Ï±th clinical trial of a gene supplementation therapy for inherited retinal disease using a recombinant AAV Í¾rAAVÍ¿ vector. We are currently investigating the safety and potential efficacy of new optimized vectors in trials with a similar design and protocol to this proposed trial: x In MGTÏ¬Ï¬Ï¯ we are investigating an optimized rAAVÏ®Í¬Ï± vector for delivery of RPEÏ²Ï± to adults and children with Leber Congenital Amaurosis caused by mutations in RPEÏ²Ï± Í¾ C h i e f Investigator: Í¿ x In MGTÏ¬Ï¬Ï² we are investigating an rAAVÏ®Í¬Ï´ vector for delivery of CNGBÏ¯ to adults and children with Achromatopsia caused by mutations in CNGBÏ¯ Í¾Chief Investigator: Í¿ x In MGTÏ¬Ï¬Ïµ we are investigating an rAAVÏ®Í¬Ï± vector for delivery of RPGR to adults and children with XÍ²linked Retinitis Pigmentosa caused by mutations in RPGR Í¾Chief Investigator: Í¿ Notably we will be using the same serotype in the trial herein for CNGAÏ¯ Í¾AAVÏ®Í¬Ï´Í¿ as has been used in our completed human clinical trial for CNGBÏ¯ Í¾AAVÏ®Í¬Ï´Í¿. We administered AAVÏ´ vector to Ï®Ï¯ participants in total Í¾Ï­Ï­ adults and Ï­Ï® childrenÍ¿. A total of Ï¯ serious adverse events Í¾SAEâ€™sÍ¿ were reported in the CNGBÏ¯ study, Ï® of which were considered at least possibly related to ATIMP. These were unexpected and were, therefore, reported as suspected unexpected serious adverse reactions"
16,page_16,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ï³ of Ï²Ï´ Í¾SUSARsÍ¿. They are further discussed in section Ï°.Ï­.Ï±. Overall, we judge that the safety profile supports the use of AAVÏ´ vector for children in this trial for CNGAÏ¯, given that children are more likely to benefit than adults. Í¶Ç¤Í³Ç¤Í¶ RaÂ–iÂ‘ÂaÂe In CNGAÏ¯Í²related Achromatopsia, delivery of a cDNA sequence encoding a functional CNGAÏ¯ protein using gene supplementation could lead to measurable improvements in visual function within Ï² months. There is currently no effective treatment available for most hereditary retinal disorders including Achromatopsia. This condition is characterised by absent Í¾or markedly reducedÍ¿ cone function resulting in profound reduction in visual acuity, complete lack of Í¾or markedly reducedÍ¿ colour vision, marked photophobia and nystagmus. The CNGAÏ¯ gene encodes the alpha subunit of the cone photoreceptorÍ²specific cGMPÍ²gated cation channel, which is critical for cellular responses to light. Absence of this alpha subunit results in absentÍ¬extremely poor cone function and hence very poor daylight vision. Although loss of cone photoreceptor cells may occur in a limited number of patients, the rate of cell death is very slow, resulting in retinas containing surviving but nonÍ²functioning cones. Improvement of cone function by provision of CNGAÏ¯ could provide a clear, rapid and reliable measure of outcome. Furthermore, the relatively nonÍ²progressive nature of Achromatopsia, with extended survival of cone photoreceptors, means that the window of opportunity for effective intervention by gene supplementation may extend into adulthood. However, since Achromatopsia results in marked visual impairment from birth, associated abnormal development of physiological coneÍ²dependent neuronal circuits, including that of the visual cortex, may limit the potential for older individuals to benefit from therapeutic restoration of retinal function. Since visual cortical plasticity is known to be greater in younger children, we will recruit children into the dose escalation phase of the study to provide the greatest opportunity for benefit. The totality of the data from paediatric subjects enrolled in the UK and adult subjects enrolled in the U.S. in this dose escalation study will be reviewed and inform the design of a future Phase ll interventional trial prior to its initiation. Í¶Ç¤Í³Ç¤Í· AÂ•Â•eÂ•Â•ÂeÂÂ– aÂd ÂaÂageÂeÂÂ– Â‘f Â”iÂ•k A gene therapy trial in human volunteers should not put the participants at disproportionate risk and for this reason should be restricted to individuals with serious disorders where effective treatments are not available. CNGAÏ¯Í²related Achromatopsia results in profound sight impairment from birth or early infancy. The condition is currently untreatable, but there is a real possibility that gene therapy could offer a significant benefit in terms of improved sight and quality of life Í¾QOLÍ¿, based on own experience from the existing clinical trials for ocular gene therapy, subsequent ocular gene therapy trials elsewhere Í¾Maguire, et al Ï®Ï¬Ï¬Ï´; Cideciyan, AV et al Ï®Ï¬Ï¬Ï´ and Ï®Ï¬Ï­Ï¯Í¿, the ongoing programme of work in ocular gene therapy trials investigating the safety and efficacy of CNGBÏ¯ as a treatment for Achromatopsia, and preÍ²clinical data demonstrating improved outcome in both CNGBÏ¯Í² and CNGAÏ¯Í²related Achromatopsia. Possible benefits of improved coneÍ²photoreceptor function include, improved visual acuity, improved colour perception, and relief from disabling photophobia. The safety of the proposed approach will be enhanced by restricting transgene expression to the target tissue by virtue of rAAV vector tropism and the coneÍ²specific promoter sequence used, and by restricting the intervention to one eye only in each participant. The risk of adverse effects will be"
17,page_17,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ï´ of Ï²Ï´ further minimised by minimising the volume of vector suspension administered and by targeting it surgically to the cone rich region of the central retina. Risks to participant safety in relation to the ATIMP are classified using the MHRA definition as Type C Í¾Markedly higher than the risk of standard medical careÍ¿. General risk management and the experience from all ongoing trials to date and will include, detailed review of all participants prior to administration of ATIMP, appropriate protocol design to identify potential short and long term risks appropriate time interval between ATIMP administration to successive participants and further limiting the risks to the child participants by first demonstrating an acceptable safety profile in both adults and children, with a similar vector, in a separate trial, MGTÏ¬Ï¬Ï². . Details of specific risks and their management strategies are outlined below. ÍºÇ¤Í·Ç¤Í»Ç¤Í· RiÂ•k Â‘f iÂÂÂ—Âe Â”eÂ•Â’Â‘ÂÂ•eÂ• Â–Â‘ AAVÍ¾Ç¦hGÍ·Ç¤Í½Â’Ç¤cÂ‘CNGAÍ¹ The main risk of inflammation will be during the early postoperative period after ATIMP administration and before vector capsids are degraded. This risk will be minimised by preÍ² and postÍ²operative prophylactic treatment using topical and systemic corticosteroids. Any persistent intraocular inflammation will be managed by topical corticosteroid therapy and systemic corticosteroids where indicated. The participants will be closely followed up with a schedule of frequent assessments to identify and address any adverse events promptly. In the first clinical trial of gene therapy Í¾MGTÏ¬Ï¬Ï¯Í¿, intraÍ²ocular delivery of an AAVÏ®Í¬Ï® vector was followed by transient intraocular inflammation in Ï¯ of Ï­Ï® participants. In our subsequent trials with the intraocular administration of AAVÏ± and AAVÏ´ vectors has been well tolerated in the majority of participants. Similar episodes of intraocular inflammation involving the posterior segment in a minority of participants but all have responded to further administration of topical and systemic corticosteroids. Of the Ï® SUSARs reported in the CNGBÏ¯ trial, the first, a panuveitis Í¾MRN Ï®Ï¬Ï­Ï³Í²UKÍ²Ï¬Ï¬Ï¬Ï¬Ï¬Ï³Í¿, met the definition of a dose limiting event Í¾DLEÍ¿ Í¾i.e. a reduction in visual acuity by greater than Ï­Ï± Early Treatment Diabetic Retinopathy Study Î€ETDRSÎ lettersÍ¿ and responded favourably and promptly to treatment with additional corticosteroids. In the second SUSAR Í¾MRN Ï®Ï¬Ï­Ï´Í²UKÍ²Ï¬Ï¬Ï¬Ï¬Ï¬Ï¯Í¿, a Ï­Ï¯ year old female participant was administered vector at the higher dose of Ï­.Ï¬ x Ï­Ï¬Ï­Ï® vgÍ¬mL. An anterior Í¬ intermediate uveitis was reported, which did not itself constitute an SAE, but was associated with a temporary reduction in visual acuity by greater than Ï­Ï± ETDRS and was, therefore, a dose limiting event that responded favourably and promptly to treatment with additional corticosteroids. ÍºÇ¤Í·Ç¤Í»Ç¤Í¸ RiÂ•k Â‘f Â˜ecÂ–Â‘Â” Â–Â”aÂÂ•ÂiÂ•Â•iÂ‘Â Â–Â‘ Â‘Â–heÂ” Â‘Â”gaÂÂ• Biodistribution studies suggest that following subretinal injection of AAV, anterograde and transÍ²synaptic transport of small amounts of vector genome from the retina to central visual structures may occur Í¾Stieger, et al Ï®Ï¬Ï¬Ï´Í¿. This is considered most likely to result from off target transduction of retinal ganglion cells following reflux of vector suspension into the vitreous. Since only tiny amounts of vector are likely to reach the brain and a cone photoreceptorÍ²specific promoter will be used, the possibility of transgene expression causing toxicity in the brain is considered to be highly unlikely. Minimal vector amounts Í¾i.e. a few hundred vector genome copiesÍ¿ might be traced in other organs like lymph nodes, spleen and liver but similarly to the brain; transgene expression causing toxicity is highly unlikely due to the cone photoreceptorÍ²specific promoter."
18,page_18,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 1Ïµ of Ï²Ï´ ÍºÇ¤Í·Ç¤Í»Ç¤Í¹ RiÂ•kÂ• Â‘f iÂÂ•eÂ”Â–iÂ‘Âal ÂÂ—Â–ageÂeÂ•iÂ• aÂd Â‘ÂcÂ‘geÂeÂ•iÂ• The possibility of oncogenic events due to vectorÍ²mediated insertional mutagenesis cannot be excluded with certainty, but available evidence suggests it to be unlikely given that Í¾iÍ¿ AAV vector genomes integrate into host chromosomes at a very low frequency Í¾Nowrouzi, et al Ï®Ï¬Ï­Ï®Í¿, Í¾iiÍ¿ a limited number of AAV particles will be administered, and Í¾iiiÍ¿ the eye predominantly contains nonÍ²dividing cells and consequently ocular tumours are very rare. Furthermore, oncogenesis has not been reported following injection of AAV into thousands of rodent eyes. Even when we injected AAV vectors intraocularly in a large number of tumourÍ²prone pÏ±Ï¯Í²Í¬Í² m i c e , w e f o u n d n o e v i d e n c e o f m a l i g n a n t transformation of retinal cells Í¾Balaggan, et al Ï®Ï¬Ï­Ï®Í¿. In the highly unlikely event that an intraocular tumour does arise, the comprehensive monitoring procedures described in Section Ï±.Ï°.Ï®.Ï¯ of the protocol will enable early detection and thus prompt appropriate management. ÍºÇ¤Í·Ç¤Í»Ç¤Íº RiÂ•k Â‘f geÂ”ÂliÂe Â–Â”aÂÂ•ÂiÂ•Â•iÂ‘Â The risk of inadvertent germline transmission is very small. In a number of studies using a variety of animal models involving various routes of administration, including intraocular injection, inadvertent germline transmission by AAV vectors has not been detected. Similarly, we detected no vector genomes in semen in our previous retinal gene therapy clinical trial Í¾Bainbridge, et al Ï®Ï¬Ï¬Ï´Í¿. Systemic intravascular administration of rAAVÏ® to deliver factor IX in haemophilia B, can lead to vector sequences detectable in semen, though not sperm for a short period Í¾Manno et al Ï®Ï¬Ï¬Ï²Í¿. However, in this instance doses ranging from Ï´ x Ï­Ï¬Ï­Ï¬ to Ï® x Ï­Ï¬Ï­Ï® vgÍ¬kg were administered, considerably higher than the doses proposed for subretinal injection in this study. Whilst this indicates there may be some potential for inadvertent germline transmission following the systemic delivery of high doses of vector, the possibility of such an event following the microsurgical delivery of tiny amounts of vector to intraocular compartments is considered to be remote. Pregnant or nursing Í¾lactatingÍ¿ women will be excluded. Female patients of childbearing potential Í¾e.g., are menstruating or could reach menarche during the studyÍ¿ should be counselled on the need for contraception should they be sexually active or, in the opinion of the Investigator, likely to be sexually active. Such subjects must agree to use an effective form of birth control Í¾hormonal or double barrier method of birth controlÍ¿ for at least Ï­Ï® months following ATIMP administration. Male patients who are sexually active must agree to use barrier and spermicide form of contraceptive during intercourse while taking the IMP and for at least Ï­Ï® months after stopping treatment. Acceptable hormonal methods of contraception include combined pill, contraceptive implant, injection or patch, hormonal coil or progestogenÍ²only pill. Despite similar advice and protocol requirements across all trials, one pregnancy Í¾MRN Ï®Ï¬Ï­Ï´Í²UKÍ²Ï¬Ï¬Ï¬Ï¬Ï¬Ï®Í¿ has been reported in our MGTÏ¬Ï¬Ï° trial, the longerÍ²term followÍ²up trial for the MGTÏ¬Ï¬Ï¯ retinal dystrophy trial of gene therapy for RPEÏ²Ï± disease, with conception approximately Ï± months following vector administration and normal delivery of a healthy infant at fullÍ²term. The most recent followÍ²up reports a positive outcome with both mother and infant being well. ÍºÇ¤Í·Ç¤Í»Ç¤Í» RiÂ•k Â‘f Â•Â—Â”gical adÂ˜eÂ”Â•e effecÂ–Â• The risk of significant surgical adverse effects is similar to the standard surgical care for other common forms of vitreoÍ²retinal disorders, including bleeding in the eye, infection and increased pressure inside the eye. To manage the risk of surgical adverse events, only highly experienced surgeons will perform"
19,page_19,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 20 of Ï²Ï´ the procedure. Complications of surgery are typically managed effectively by medication or further surgical intervention but can rarely result in lasting harm to sight. The risk of lasting severe impairment of sight from vitrectomy surgery is approximately Ï­ in Ï­Ï¬Ï¬Ï¬. Reduction in foveal retinal thickness has been previously reported in a proportion of patients in both our first RPEÏ²Ï± trial and other RPEÏ²Ï± clinical trials, believed to result from temporary retinal detachment which is a deliberate consequence of targeted administration of the vector suspension, but no other significant surgical adverse effects. However, in subsequent trials the use of a modified surgical technique that minimises the height of retinal detachment has resulted in no significant effect on foveal retinal thickness Í´ most notably retinal thickness has been stable postÍ²intervention in all Ï®Ï¯ participants Í¾Ï­Ï­ adults and Ï­Ï® childrenÍ¿ in the CNGBÏ¯ trial. Delivery of ATIMP to the subretinal space will be performed by standard surgical vitrectomy. This will involve a Ï¯Í²port pars plana vitrectomy followed by injection of ATIMP using a fine cannula through small retinotomies, resulting in a temporary retinal detachment. Previous gene therapy clinical trials have shown that the bleb of subretinal ATIMP suspension can be expected to resolve spontaneously over the course of the first Ï®Ï° to Ï°Ï´ hours postoperatively as the fluid is absorbed by the underlying retinal pigment epithelium. Potential complications of this surgery specifically include persistence of the subretinal vector bleb, the development of retinal tears, elevated intraocular pressure and persistent postoperative intraocular inflammation. Persistently elevated intraocular pressure may result in glaucoma and vision loss; likewise, persistent inflammation may result in vision loss. Elevated intraocular pressure will be managed by topical therapy; with systemic therapy where indicated with specialist advice sought as required. Any potential risk to visual function will be minimised by limiting ATIMP delivery to the area of retina most likely to benefit, and by leaving the contralateral eye untreated. Retinal detachment caused by persistent vector bleb or intraoperative retinal tear is expected to occur in fewer than Ï­ in Ï­Ï¬Ï¬ procedures and can be effectively managed in the majority by retinopexy, with or without intraocular tamponade. Vitrectomy surgery is a standard technique, commonly performed for a wide range of indications. Injection of fluids under the retina is less commonly performed but is a standard step in surgery for subretinal haemorrhage, and an adjunctive technique in the management of retinal detachment. ÍºÇ¤Í·Ç¤Í»Ç¤Í¼ RiÂ•k Â‘f adÂ˜eÂ”Â•e effecÂ–Â• Â‘f cÂ‘Â”Â–icÂ‘Â•Â–eÂ”Â‘idÂ• Candidates will be screened for contraÍ²indications to transient immune suppression by corticosteroids; in particular, a history of uncontrolled hypertension, diabetes mellitus, tuberculosis, renal impairment, osteoporosis, gastric ulceration, severe affective disorder immunocompromised status and increased risk of infections.Possible adverse effects of shortÍ²term systemic corticosteroid use include increases in blood pressure and blood sugar, weight gain, changes in mood or behaviour, increased risk of infections, increased intraocular pressure and cataracts. Local steroids used on or near the eye can cause increased intraocular pressure and cataracts. The possibility of steroidÍ²induced adverse effects will be monitored regularly. In particular, blood pressure and blood glucose will be measured, as will renal function and liver function Í¾at baseline, Ï­ day, Ï³ days, Ï® weeks and Ï° weeks after surgeryÍ¿. Common and expected laboratory findings observed in the other ongoing studies utilising prophylactic corticosteroids have included but are not limited to: leucocytosis, neutrophilia, hyperglycaemia. If the latter should occur, then a referral to a diabetologist would occur. On occasion"
20,page_20,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 21 of Ï²Ï´ mild transaminase changes have occurred but are mild and selfÍ²limiting. All the above have resolved with the tapering of the corticosteroids. ÍºÇ¤Í·Ç¤Í»Ç¤Í½ RiÂ•kÂ• Â‘f iÂÂ˜eÂ•Â–igaÂ–iÂ‘ÂÂ• Â’eÂ”fÂ‘Â”Âed dÂ—Â”iÂg aÂ•Â•eÂ•Â•ÂeÂÂ– aÂd fÂ‘llÂ‘Â™ Â—Â’ The majority of investigations are nonÍ²invasive routine clinical tests and presents no significant risk. Venepuncture causes temporary discomfort, occasionally bruisingÍ¬swelling and rarely infection at the site of puncture. The participants will have all risks discussed during the consent process and are able to read them additionally in the Participant Information Sheet Í¾PISÍ¿. ÍºÇ¤Í·Ç¤Í»Ç¤Í¾ RiÂ•k Â‘f Â”Â‘d Â’hÂ‘Â–Â‘Â”eceÂ’Â–Â‘Â” dÂ›Â•fÂ—ÂcÂ–iÂ‘Â The aim of the intervention is to improve the function of cone photoreceptor cells. Rod photoreceptors exposed to the ATIMP are not expected to benefit but may be subject to adverse effects of the surgical intervention or ATIMP. We plan to minimize any adverse effect by targeting the ATIMP to the central retina where the cone photoreceptors predominate. In addition, the use of a cone specific promoter to drive CNGAÏ¯ expression specifically in cones, will minimise inappropriate ectopic expression in rod photoreceptors. Moreover, should cone photoreceptorÍ²mediated vision be improved by the gene therapy, any dysfunction of rod photoreceptor cells is expected to be evident only in a dimly illuminated environment. No change in rod function has been described to date in the animal models Í¾mouse and dogÍ¿ used to demonstrate the potential of gene supplementation therapy in CNGAÏ¯Í²associated Achromatopsia. There has also been no change in rod function in any of the Ï®Ï¯ participants Í¾Ï­Ï­ adults and Ïµ childrenÍ¿ in our current CNGBÏ¯ trial. ÍºÇ¤Í·Ç¤Í»Ç¤Í¿ RiÂ•k Â‘f Â–hiÂÂiÂg Â‘f Â–he fÂ‘Â˜ea Thinning of the retina in the macula Í¾macular thinningÍ¿ has been detected in Ï²Í¬Ï­Ï¬ participants after subfoveal delivery of AAV vector in our previous RPEÏ²Ï± clinical trial Í¾MGTÏ¬Ï¬Ï¯Í¿. Macular thinning was typically apparent within Ï¯ months and subsequently nonÍ²progressive. Associated thinning of the photoreceptor cell Í¾outer nuclearÍ¿ layer was evident, with variable disruption of the photoreceptor ellipsoid Í¾inner segmentÍ¿ zone. However, in subsequent current trials the use of a modified surgical technique that minimises the height of retinal detachment has resulted in no significant effect on retinal thickness Í´ most notably retinal thickness has been stable postÍ²intervention in all Ï®Ï¯ participants Í¾Ï­Ï­ adults and Ïµ childrenÍ¿ in the CNGBÏ¯ trial. Since the central macula comprises predominantly of cone photoreceptor cells that have no function in achromatopsia, therefore it is not expected that macular thinning to affect vision significantly in this trial. The participants intensive schedule of assessments Í¾Table Ï±.Ï²Í¿ has been designed to assess vision frequently. ÍºÇ¤Í·Ç¤Í»Ç¤Í·Í¶ RiÂ•k Â‘f Â˜iÂ•Â—al iÂbalaÂce Individuals affected by Achromatopsia have severe sight impairment with no colour perception from birth. Improvement of retinal function by intervention later in development is expected to lead to new visual experiences. While these are expected to be positive, unpleasant visual sensations might also be experienced. The participants are made aware of this risk from the initial consenting process."
21,page_21,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 22 of Ï²Ï´ ÍºÇ¤Í·Ç¤Í»Ç¤Í·Í· CÂ‘ÂclÂ—Â•iÂ‘Â Â‘Â Â–he Â”iÂ•kÇ¦beÂefiÂ– Â”aÂ–iÂ‘ In summary, the risks associated with the intervention are justified by the potential for individual participants to benefit, and by the scientific value of the trial to the development of treatments for other individuals similarly affected. Emerging safety data from the ongoing CNGBÏ¯ Achromatopsia trial provides further justification for the administration of vector to children in the dose escalation part of the current trial. Í¶Ç¤Í³Ç¤Í¸ EÂšÂ’ÂaÂaÂ–iÂ‘Â fÂ‘Â” ChÂ‘ice Â‘f CÂ‘ÂÂ’aÂ”aÂ–Â‘Â”Â• There is no currently approved treatment for Achromatopsia caused by mutations in CNGAÏ¯Í˜ The comparator will be the contralateral eye and supplementary data collected as part of a prospective, parallel natural history study of patients with Achromatopsia. The totality of the data from paediatric subjects enrolled in the UK and adult subjects enrolled in the U.S. will be reviewed and inform the design of a future Phase ll interventional study. Í¶Ç¤Í´ ObjecÂ–iÂ˜eÂ• Í¶Ç¤Í´Ç¤Í³ PÂ”iÂaÂ”Â› ObjecÂ–iÂ˜e The primary research objective is to assess the safety of an AAVÏ®Í¬Ï´ vector for hCNGAÏ¯ g e n e replacement in the retina. Safety is defined as: Safety is defined as the absence of an ATIMPÍ²related: x Reduction in visual acuity by Ï­Ï± ETDRS letters or more that fails to resolve to within Ï­Ï± letters of baseline in a Ï°Í²week period once prophylactic treatment commences x Severe unresponsive inflammation Í¾defined belowÍ¿ x Infective endophthalmitis x Ocular malignancy x Grade III or above nonÍ²ocular SUSAR Í¾see section Ï±.Ï­Ï­.Ï¯Í¿ Severe unresponsive inflammation will be defined according to the Standardisation of Uveitis Nomenclature Í¾SUNÍ¿ Working Group grading system Í¾Jabs et AlÍ˜ Ï®Ï¬Ï¬Ï±Í¿ i.e. x anterior chamber cells Ï¯Ğ½ Í¾Ï®Ï²Í²Ï±Ï¬ cells in a field size of Ï­mm x Ï­Í²mm slitÍ²beamÍ¿, or x anterior chamber flare Ï¯Ğ½ Í¾marked, iris and lens details hazyÍ¿, or x vitreous haze Ï¯Ğ½ Í¾Ophthalmology Ï­ÏµÏ´Ï±; ÏµÏ®:Ï°Ï²Ï³Í²Ï³Ï­Í¿ that fails to improve by Ï® steps Í¾or to grade Ï¬Í¿ during a Ï²Í²week period. Í¶Ç¤Í´Ç¤Í´ SecÂ‘ÂdaÂ”Â› ObjecÂ–iÂ˜e The secondary research objective is to determine whether an AAVÏ®Í¬Ï´ vector for hCNGAÏ¯ g e n e replacement in the retina can improve retinal function, visual function and quality of life. Í¶Ç¤Íµ TÂ”iaÂ DeÂ•igÂ This is an openÍ²label phase IÍ¬II doseÍ²escalation trial to determine the safety and efficacy of subretinal administration of the ATIMP in children with CNGAÏ¯Í²related Achromatopsia. Paediatric participants for the purposes of this protocol are participants aged up to and inclusive of Ï­Ï± years of age. As part of the risk mitigation strategy for this protocol, ATIMP administration will first be administered to at least one older child participant Í¾Ï­Ï­Í² Ï­Ï± years of ageÍ¿ from each cohort before proceeding to younger participants."
22,page_22,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 23 of Ï²Ï´ In this dose escalation study, up to Ï­Ï´ participants will be administered one of Ï¯ different doses of the ATIMP in cohorts of Ï¯ participants at a time in the first instance. Based on emerging safety data, the SDMC will make a recommendation on the dose to administer to the next cohort of participants. The SDMC may recommend additional participants at a given dose before making their recommendation on how to proceed to the next dose. Paediatric cases for the purposes of this protocol are defined as participants aged up to and inclusive of Ï­Ï± years. In addition to the paediatric cohorts in the UK, an additional cohort of Ï® adult subjects will be enrolled in the US. The adult cohort will be administered the highest dose studied from the paediatric cohorts based on when the first adult subject is identified and ready to be enrolled. The SDMC will review the data from all subjects Í¾paediatric and adultÍ¿ in this dose escalation study. Safety and efficacy will be assessed for Ï² months following the intervention by clinical examination and special investigations according to the schedule in section Ï±.Ï² of the protocol. The totality of the data from paediatric subjects enrolled in the UK and adult subjects enrolled in the US will be reviewed and inform the design of a future Phase ll interventional study. ÍºÇ¤Í¹Ç¤Í·Ç¤Í· SeÂ’aÂ”aÂ–e lÂ‘ÂgeÂ” Â–eÂ”Â fÂ‘llÂ‘Â™ Â—Â’ Â•Â–Â—dÂ› In line with current CHMP and FDA guidance, the ATIMP safety is further assessed by a separate longer term follow up study of Ï²Ï¬ months duration, if the participants Í¬ caregiverâ€™s consent and only once they have reached the Ï²Í²month timepoint in the current study. The duration of longÍ²term followÍ²up is therefore consistent with the recommendations of the current CHMP Guideline on FollowÍ²up of Patients Administered with Gene Therapy Medicinal Products Í¾EMEAÍ¬CHMPÍ¬GTWPÍ¬Ï²Ï¬Ï°Ï¯Ï²Í¬Ï®Ï¬Ï¬Ï³Í¿ of Ï®Ï® October Ï®Ï¬Ï¬Ïµ, where it is stated that, for viral vectors without integration, latency or reactivation potential, a brief clinical history and sample testing should be performed preÍ²treatment, at Ï¯, Ï² and Ï­Ï® months after treatment, and then yearly thereafter for a minimum of Ï± years Í¾and, if nonÍ²clinical tests or evidence from other clinical trials using identical vectors or modifications of vectors indicate a potential for integration or late reÍ²activation, the monitoring should be extended to continue yearly after those Ï± years until data indicate that there is no longer any risk to be followedÍ¿. Further, although the FDA Guidance February Ï®Ï¬Ï®Ï¬ Í¾Long Term FollowÍ²up After Administration of Human Gene Therapy Products: Guidance for IndustryÍ¿ recommends a standard Ï­Ï±Í²year period of followÍ²up, it is also noted that a shorter period of follow up may be appropriate if the ATIMP does not integrate and has no potential for latency and reactivation. The followÍ²up study will be a nonÍ²intervention study designed to collect data on longer term safety and efficacy at the equivalent of Ïµ, Ï­Ï®, Ï®Ï°, Ï¯Ï², Ï°Ï´ and Ï²Ï¬ months following ATIMP administration; as such, participants in both studies will be followed up more frequently than recommended in the guidance, as additional assessments following ATIMP administration are included in the initial study Í¾at weeks Ï­, Ï®, Ï° and Ï²Í¿ and in the longÍ²term follow up study Í¾at months Ïµ and Ï­Ï´Í¿. TheÍ²follow up study will have a separate protocol, participant information and consent process, and will be submitted for separate ethical review. Participants in the current study will be strongly encouraged to join the follow up study as part of their ongoing clinical review, but there will be no obligation on their part to do so. It is acknowledged that, despite encouragement, participants may elect not to participate in the longÍ²term followÍ²up study; however, in this motivated population, where individuals are typically monitored by their specialist closely and regularly, this is considered unlikely."
23,page_23,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ï° of Ï²Ï´ Í¶Ç¤ÍµÇ¤Í´ IMP adÂiÂiÂ•Â–Â”aÂ–iÂ‘Â ReÂ˜ieÂ™ aÂd DÂ‘Â•e EÂ•caÂaÂ–iÂ‘Â CÂ”iÂ–eÂ”ia aÂd PÂ”Â‘ceÂ•Â• Up to Ï­Ï´ participants Í¾as defined in section Ï°.Ï¯Í¿ will be administered a single dose of ATIMP in a total volume of Ï¬.Ï±mL, according to the below doseÍ²escalation criteria. These are anticipated to be as described below: Ï­Í¿ low dose Ï®Í¿ intermediate dose Ï¯Í¿ high dose In order to explore optimal dosing within safe limits, additional doses may be administered in order to maximise therapeutic effect, whilst maintaining the safety profile of the product. Any dose that differs from those described above will not exceed the highest titre of . The Chief Investigator, Medical Monitor and SDMC chair will confirm additional doses in advance of them being administered. The actual titre to be administered will be recorded in the eCRF. ÍºÇ¤Í¹Ç¤Í¸Ç¤Í· DÂ‘Â•e eÂ•calaÂ–iÂ‘Â cÂ”iÂ–eÂ”ia aÂd DÂ‘Â•e LiÂiÂ–iÂg EÂ˜eÂÂ–Â• Dose escalation will be managed according to review of available and emerging data on the subjects administered ATIMP top date and the occurrence, if any, of DLEâ€™s or medically important events. An SDMC will review data from a minimum of Ï² weeks of follow up from each cohort of participants Í¾at least one older child, Ï­Ï­Í²Ï­Ï± years of age per cohortÍ¿, before recommending the next dose to be assessed in a further cohort of participants or to additional participants at the same dose level. A DLE is defined as any of the below occurring during the Ï² weeks following administration, at least possibly related to the ATIMP, not surgery alone: x A reduction in visual acuity by Ï­Ï± ETDRS letters or more that fails to resolve to within Ï­Ï± letters of baseline in a Ï°Í²week period once prophylactic treatment commences x Severe unresponsive inflammation Í¾defined belowÍ¿Î x Infective endophthalmitis x Ocular malignancy x Grade III or above nonÍ²ocular SUSAR Í¾see section Ï±.Ï­Ï­.Ï¯Í¿ Î Severe unresponsive inflammation will be defined according to the Standardisation of Uveitis Nomenclature Í¾SUNÍ¿ Working Group grading system Í¾Jabs et AlÍ˜ Ï®Ï¬Ï¬Ï±Í¿ i.e. x anterior chamber cells Ï¯Ğ½ Í¾Ï®Ï²Í²Ï±Ï¬ cells in a field size of Ï­mm x Ï­Í²mm slitÍ²beamÍ¿, or x anterior chamber flare Ï¯Ğ½ Í¾marked, iris and lens details hazyÍ¿, or x vitreous haze Ï¯Ğ½ Í¾Ophthalmology Ï­ÏµÏ´Ï±; ÏµÏ®:Ï°Ï²Ï³Í²Ï³Ï­Í¿ that fails to improve by Ï® steps Í¾or to grade Ï¬Í¿ during a Ï²Í²week period. Review of safety data will be undertaken by the SDMC prior to each dose escalation. ÍºÇ¤Í¹Ç¤Í¸Ç¤Í¸ DÂ‘Â•iÂg Â’Â”Â‘ceÂ•Â• Í¶Ç¤ÍµÇ¤Í´Ç¤Í´Ç¤Í³ Cohort Í³ ATIMP will first be administered at the lowest dose to at least one older paediatric Í¾aged Ï­Ï­Í²Ï­Ï±Í¿ participant only. This participant will be monitored for signs or evidence of visual andÍ¬or systemic toxicity for a period of Ï² weeks and as per schedule of assessments Í¾section Ï±.Ï²Í¿. If there is no DLE as"
24,page_24,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ï± of Ï²Ï´ defined above after a minimum of Ï² weeks, ATIMP will continue to be administered at the same dose to Ï® additional paediatric participants. In the event of a DLE in the first cohort, a discussion will be held with the SDMC to agree a plan of action for the administration of ATIMP to further participants. The SDMC will review the data collected on this cohort up to Ï² weeks following ATIMP administration to the last participant in the cohort. Í¶Ç¤ÍµÇ¤Í´Ç¤Í´Ç¤Í´ Cohort Í´ In the event that there is no DLE or other event considered clinically relevant to the progression of the study and dose escalation in any participant in cohort Ï­ the SDMC will provide a recommend to proceed administering ATIMP at the intermediate dose level. If dose escalation proceeds, at least a single older paediatric Í¾aged Ï­Ï­Í²Ï­Ï±Í¿ participant will be administered ATIMP. If there is no DLE or other event considered clinically relevant after a minimum of Ï² weeks, ATIMP will continue to be administered at the same dose to Ï® further participants. In the event of a DLE in the first participant in the cohort, a discussion will be held with the SDMC to agree a plan of action for administering the ATIMP to further participants. The SDMC will again review the data available on this next cohort of participants up to Ï² weeks following ATIMP administration to the last participant in the cohort. Í¶Ç¤ÍµÇ¤Í´Ç¤Í´Ç¤Íµ Cohort Íµ In the event that there is no DLE Í¾or clinically relevant eventÍ¿ in any participant in previous cohorts, the SDMC may recommend administering ATIMP at the highest dose level to a single older paediatric participant Í¾aged Ï­Ï­Í²Ï­Ï± yearsÍ¿ following review of all presented safety, toxicity and if relevant efficacy data. If there is no DLE or other event considered clinically relevant to the progression of the study after a minimum of Ï² weeks, ATIMP will be administered at the same dose to Ï® further participants. In the event of a DLE in the first participant in the cohort, a discussion will be held with the SDMC to agree a plan of action for administering the ATIMP to further participants, the age and the dose. Í¶Ç¤ÍµÇ¤Í´Ç¤Í´Ç¤Í´Ç¤Í¶ AdÂ—lt CohortÇ¦United States In addition to the paediatric cohorts in the United Kingdom an additional cohort of Ï® adult subjects, Ï­Ï´ years of age or older will be administered ATIMP at the highest dose studied from the paediatric cohorts based on when the first adult subject is identified and ready to be enrolled. The SDMC will also review the data from the adult cohort. Í¶Ç¤ÍµÇ¤Í´Ç¤Í´Ç¤Í· Additional considerations In the event of a DLE in one of the participants at a given dose, the cohort may be expanded at the same dose level. The SDMC will review the safety data and recommend that additional participants may be treated at this dose. The SDMC may recommend that the same dose of ATIMP is administered to additional participants. The dose escalation will continue until SDMC are comfortable on review of the accumulating data, to recommend a maximum dose to be administered, or Ï¯ participants have been administered the highest dose without any DLEs, or until at least Ï® participants among a cohort of Ï¯ to Ï² participants experience DLEs Í¾i.e., ÑˆÏ¯Ï¯Ğ¹ of patients with a DLE at that dose levelÍ¿, in which case the recommended dose will be the level below this dose. In the event that Ï­ or Ï® DLEs are seen at the first dose level, the SDMC may recommend administering a lower dose to that described in the protocol to a cohort of participants."
25,page_25,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ï² of Ï²Ï´ Table Ï­: Dose escalation table Í· MeÂ–hÂ‘dÂ• Í·Ç¤Í³ SiÂ–e SeÂecÂ–iÂ‘Â The trial sponsor MeiraGTx UK II Ltd. has overall responsibility for site and investigator selection. Í·Ç¤Í³Ç¤Í³ SÂ–Â—dÂ› SeÂ–Â–iÂg The study settings are academic hospitals and academic research centres selected for their ability to perform the intervention and assessments required of this protocol. Data will be collected from multiple centres in the United Kingdom Í¾UKÍ¿ and in the United StatesÍ¾USÍ¿. Í·Ç¤Í³Ç¤Í´ SiÂ–eÈ€IÂÂ˜eÂ•Â–igaÂ–Â‘Â” EÂigibiÂiÂ–Â› CÂ”iÂ–eÂ”ia Once a site has been assessed as being suitable to participate in the trial, the trial team will provide them with a copy of this protocol and the ATIMP Investigator Brochure. To participate in this trial of gene therapy for Achromatopsia Í¾CNGAÏ¯Í¿, investigators and trial sites must fulfil a set of criteria that have been agreed by the Clinical Management Team Í¾CMTÍ¿ as defined below. Eligibility criteria: x A named clinician is willing and appropriate to take Principal Investigator responsibility x Suitably trained staff are available to recruit participants, enter data and collect samples x Suitably trained and certified staff are available to undertake clinical assessments x The site has access to a sufficient number of potential participants to meet their enrolment objectives x The site has access to all specialised equipmentÍ¬devices needed for clinical assessments"
26,page_26,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ï³ of Ï²Ï´ x The site should be able to archive traceability data for a minimum of Ï¯Ï¬ yearsâ€™ post expiry date of the ATIMP x The site should be able to store, prepare, dispense, and administer ATIMP appropriately Trial sites meeting eligibility criteria and that are accepted by the CMT as being suitable to recruit to the trial, will be issued with the Gene Therapy for Achromatopsia Í¾CNGAÏ¯Í¿ Trial Master File Í¾TMFÍ¿ documentation to use when applying for local approvals as applicable. Í»Ç¤Í·Ç¤Í¸Ç¤Í· PÂ”iÂciÂ’al IÂÂ˜eÂ•Â–igaÂ–Â‘Â”Ç¯Â• È‹PIÈŒ QÂ—alificaÂ–iÂ‘ÂÂ• aÂd AgÂ”eeÂeÂÂ–Â• The investigatorÍ¾sÍ¿ must be willing to sign a Clinical Trial Agreement and an Investigator Agreement to comply with the trial protocol Í¾confirming their specific roles and responsibilities relating to the trial, and that their site is willing and able to comply with the requirements of the trialÍ¿. This includes confirmation of appropriate qualifications, familiarity with the appropriate use of any investigational products, agreement to comply with the principles of GCP, maintaining up to date GCP certification, to permit monitoring and audit as necessary at the site, and to supervise and maintain documented evidence of all staff at the site who have been delegated significant trial related duties. Í»Ç¤Í·Ç¤Í¸Ç¤Í¸ ReÂ•Â‘Â—Â”ciÂg aÂ– Â•iÂ–e The investigatorÍ¾sÍ¿ should be able to demonstrate a potential for recruiting the required number of suitable participants within the agreed recruitment period Í¾i.e., the investigatorÍ¾sÍ¿ regularly provide clinical care for the target populationÍ¿. They should also have an adequate number of qualified staff and facilities available for the foreseen duration of the trial to enable them to conduct the trial properly and safely. Sites will be expected to complete a delegation of responsibilities log and provide staff contact details. Í·Ç¤Í´ SiÂ–e aÂ’Â’Â”Â‘Â˜aÂ aÂd acÂ–iÂ˜aÂ–iÂ‘Â The regulatory authorisations for the trial require that the Medicines and Healthcare products Regulatory Agency Í¾MHRAÍ¿ and US Food and Drug Administration Í¾FDAÍ¿ are supplied with the names and addresses of all participating site Principal Investigators. Clinical Operations staff at MeiraGTx UK II Ltd. will ensure this information is provided to both the MHRA and FDA. On receipt of the signed Clinical Trial Agreement and Investigator Agreement, approved delegation of responsibilities log and staff contact details, written confirmation will be sent to the site PI. The trial manager or delegate will notify the PI in writing of the plans for site initiation. Sites will not be permitted to recruit any patients until a letter for activation has been issued. The site must conduct the trial in compliance with the protocol as agreed by the Sponsor and, by the competent authorities, and which was given favourable opinion by the UK Health Research Authority Í¾HRAÍ¿ and local Institutional Review Board Í¾IRBÍ¿ in the US. The PI or delegate must document and explain any deviation from the approved protocol, and communicate this to the trial team at MeiraGTx UK II Ltd."
27,page_27,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ï´ of Ï²Ï´ Í·Ç¤Íµ PaÂ”Â–iciÂ’aÂÂ–Â• Í·Ç¤ÍµÇ¤Í³ EÂigibiÂiÂ–Â› CÂ”iÂ–eÂ”ia Í»Ç¤Í¹Ç¤Í·Ç¤Í· PaÂ”Â–iciÂ’aÂÂ– Â•elecÂ–iÂ‘Â The eligibility criteria for this trial have been carefully considered and are the standards used to ensure that only medically appropriate participants are entered. Participants not meeting the criteria should not be entered into the trial for their safety, and to ensure that the trial results can be appropriately used to make future treatment decisions for other people with similar diseases or conditions. It is therefore vital that exceptions are not made to these eligibility criteria. Participants will be considered eligible for enrolment in this trial if they fulfil all the inclusion criteria and none of the exclusion criteria as defined below. Í»Ç¤Í¹Ç¤Í·Ç¤Í¸ PaÂ”Â–iciÂ’aÂÂ– IÂclÂ—Â•iÂ‘Â CÂ”iÂ–eÂ”ia Inclusion in the trial will be limited to individuals who: Ï­. Are aged Ï¯Í²Ï­Ï± years Ï®. Have Achromatopsia confirmed by a retinal specialist Í¾PIÍ¿ Ï¯. Have homozygous or compound heterozygous missense or null mutations in CNGAÏ¯ confirmed in an accredited laboratory. Segregation is highly desirable but not essential if parental samples are not available. Ï°. Have evidence of relative photoreceptor preservation at the macula assessed by OCT Ğ½Í¬Í² AO. Participants with normal ISe or minimally disrupted ISe on OCT will be prioritised. Ï±. Are able to give informed consent or assent, with or without the guidance of their parentÍ¬guardian where appropriate: children aged Ï¯Í²Ï² years will not be required to provide assent Ï². Are able to undertake ageÍ²appropriate clinical assessments at the trial sites as specified in the protocol Ï³. If female and of childbearing potential and sexually active, are willing to use an effective form of birth control Í¾hormonal or double barrier method of birth control; or abstinenceÍ¿ for at least Ï­Ï® months following ATIMP administration Í¾Section Ï°.Ï­.Ï±, Assessment and Management of RiskÍ¿ Ï´. If male and sexually active, are willing to use barrier and spermicide form of contraceptive or maintain sexual abstinence for at least Ï­Ï® months following ATIMP administration Ïµ. Females of childbearing potential will have a negative pregnancy test on the day of ATIMP administration. Participants are considered not of childbearing potential if they are preÍ²pubescent or surgically sterile Í¾i.e. they have undergone a hysterectomy or bilateral oophorectomyÍ¿ Ï­Ï¬. Are willing to give consent for the use of blood and blood components collected throughout the trial for the investigation of immune responses to the ATIMP"
28,page_28,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 2Ïµ of Ï²Ï´ Í»Ç¤Í¹Ç¤Í·Ç¤Í¹ PaÂ”Â–iciÂ’aÂÂ– EÂšclÂ—Â•iÂ‘Â CÂ”iÂ–eÂ”ia Individuals will be excluded who: Ï­. Are females who are pregnant or breastfeeding Ï®. Have uncontrolled gastroÍ²oesophageal reflux or are using nonÍ²steroidal antiÍ²inflammatory drugs on a regular basis at the time of screening Ï¯. Have a known allergy to any of the nonÍ²investigational drugs to be used in the trial as defined in Section Ï±.Ï°.Ï­ Ï°. Have participated in another research study involving an investigational medicinal therapy for ocular disease within the last Ï² months Ï±. Have any other condition that the CIÍ¬PI considers makes them inappropriate for entry into the trial, inclusive of but not limited to a history of the following: x Uncontrolled hypertension defined as a systolic value ÑˆÏ­Ï²Ï¬mmHg or diastolic value ÑˆÏ­Ï¬Ï¬mmHg. x Uncontrolled diabetes mellitus defined as an HbAÏ­c ÑˆÏµĞ¹ Í¾Ï³Ï±mmolÍ¬molÍ¿ at screening. x Any history of tuberculosis x Chronic kidney disease Í¾defined as eGFR Ñ‡Ï²Ï¬mlÍ¬min calculated using Cockroft Gault or MDRD equations. x Immunocompromised state Í¾including long term immunosuppressant therapyÍ¿. x Osteoporosis Í¾defined as presence of Ï­ or more nonÍ²traumatic â€œfragilityâ€ fractures or proven BMD of Ï®.Ï±SD less than anticipated as demonstrated on DEXA scanÍ¿. x Active peptic ulcer disease or uncontrolled gastroÍ²oesophageal reflux. x Severe affective disorder or past history of drug induced psychosis, and uncontrolled heart failure Í¾NYHA class IIÍ²IVÍ¿. Ï². Use of high dose regular nonÍ²steroidal antiÍ²inflammatory drugs at the time of screening Will be excluded from participating in the study protocol: x During the Ï² weeks prior to baseline, have had ANY of Í¾aÍ¿ confirmed SARSÍ²CoVÍ²Ï® Í¾COVIDÍ²Ï­ÏµÍ¿ infection Í¾test positiveÍ¿, OR Í¾bÍ¿ suspected SARSÍ²CoVÍ²Ï® infection Í¾clinical features without documented test resultsÍ¿, OR Í¾cÍ¿ close contact with a person with known or suspected SARSÍ²CoVÍ²Ï® infection o Exception: may be included with a documented negative result for a validated SARSÍ²CoVÍ²Ï® test Í¾iÍ¿ obtained at least Ï® weeks after conditions Í¾aÍ¿, Í¾bÍ¿, Í¾cÍ¿ above Í¾timed from resolution of key clinical features if present, e.g. fever, cough, dyspneaÍ¿ AND Í¾iiÍ¿ with absence of ALL conditions Í¾aÍ¿, Í¾bÍ¿, Í¾cÍ¿ above during the period between the negative test result and the baseline study visit"
29,page_29,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 30 of Ï²Ï´ x NOTES on COVIDÍ²related exclusion: Ï­. If a patient is excluded due to recent COVIDÍ²Ï­ÏµÍ²related features, the reason for screen failure should be documented in the case report form under the exclusion criterion of having a condition for which participation would not be in the participantâ€™s interest or could confound study assessments. Ï®. The field of COVIDÍ²related testing Í¾for presence of, and immunity to, the SARSÍ²CoVÍ²Ï® virusÍ¿ is rapidly evolving. Additional testing may be performed as part of screening andÍ¬or during the study if deemed necessary by the investigator and in accordance with current regulations Í¬ guidance from authorities Í¬ standards of care. Ï¯. Have an ocular or systemic disorder that may preclude subretinal surgery andÍ¬or interfere with interpretation of the study results Ï°. Have had intraocular surgery within Ï² months of screening Ï±. Are unwilling to consider the possibility of entry into a subsequent longer term follow up study Í»Ç¤Í¹Ç¤Í·Ç¤Íº EligibiliÂ–Â› CÂ”iÂ–eÂ”ia fÂ‘Â” IÂdiÂ˜idÂ—alÂ• PeÂ”fÂ‘Â”ÂiÂg Â–he IÂÂ–eÂ”Â˜eÂÂ–iÂ‘ÂÂ• Individuals performing the interventions will be limited to those qualified by training and experience to perform those interventions. Surgery will be performed only by a qualified vitreoÍ²retinal surgeon. The ATIMP will be administered by designated individuals at each study site to promote consistency of the intervention. A training programme has been developed that involves any designated individuals being trained in person by Professor Í¾or an experienced surgeon who has been delegated this role by Prof Í¿. This may involve observations of the procedure being performed in the UK or the US. The completion of this training is one of the criteria that will be satisfied prior to site activation. Í»Ç¤Í¹Ç¤Í·Ç¤Í» CÂ‘Ç¦eÂÂ”Â‘lÂeÂÂ– GÂ—idaÂce Individuals who have participated in another research study involving an investigational medicinal therapy for ocular disease within the last Ï² months, will not be eligible for enrolment in this study. Í»Ç¤Í¹Ç¤Í·Ç¤Í¼ ScÂ”eeÂiÂg PÂ”Â‘cedÂ—Â”eÂ• Written informed consent to enter the trial must be obtained from participantsâ€™ parentsÍ¬guardiansÍ¬person with legal responsibility Í¾including legal authoritiesÍ¿, and written assent must be obtained from children aged over Ï², after explanation of the aims, methods, possible benefits and potential hazards of the trial and before any trialÍ²specific procedures are performed or any blood is taken for the trial. The only procedures that may be performed in advance of written informed consent being obtained are those that would be performed on all patients in the same situation as a usual standard of care. However, results of any procedures that were performed as part of the usual standard care within Ïµ months of the screeningÍ¬baseline window of this study and prior to enrolment on this study may be used for baselineÍ¬screening if the subjects provide informed consent for the use of the prior obtained results. Í·Ç¤ÍµÇ¤Í³Ç¤Í¸Ç¤Í³ Informed Consent ProcedÂ—re Written assent and informed consent as appropriate will be taken from each participant and parentÍ¬guardian by the chiefÍ¬principal investigator or delegated clinician following appropriate explanation of the aims, methods, possible benefits and risks of the study. The Investigator or designee"
30,page_30,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 31 of Ï²Ï´ will explain that the participants are under no obligation to enter the trial and that they can withdraw at any time during the trial, without having to give a reason, and without their clinical care being affected. The consent process will be managed during at least Ï® meetings. At an initial meeting, information will be presented to potential participants in a form appropriate to their level of understanding. The support of an independent counsellor or advisor will also be offered. Potential participants will be provided with the relevant patient information and given time Í¾a minimum of Ï®Ï° hoursÍ¿ to consider their decision. At a subsequent meeting, potential participants and their parentsÍ¬carers will be provided with a further opportunity to ask questions and to sign the consent and assent forms. Children will be invited to give their verbal Í¾noted in their medical notesÍ¿ or written assent to participation where this is age appropriate Í¾i.e., children aged over Ï² yearsÍ¿. Children aged over Ï² years will be included in the trial only if they assent to participate. Children under the age of Ï² are not required to provide assent. A copy of the signed assent and Informed Consent form will be provided to the participant. The original signed form will be retained at the study site and a copy placed in the medical notes. If new safety information results in significant changes in the riskÍ¬benefit assessment, the participant information sheet and consent form will be reviewed and updated if necessary, and participants will be reÍ²consented as appropriate. Children who become of adult age Í¾i.e. Ï­Ï² in the EUÍ¿ during the study will be reÍ²consented as adults at the time of the next visit. Í·Ç¤ÍµÇ¤Í³Ç¤Í¸Ç¤Í´ Screening Period Screening procedures will take place only after the informed consent form has been signed by the participantÍ¬parentÍ¬guardian. However, if test results are available from the subjectâ€™s routine clinical examination results within Ïµ months of the screening visit and the subject has consented to allow the use of those tests, then those screening tests will not need to be repeated. Participants will undergo genetic screening for CNGAÏ¯ mutations at an accredited laboratory prior to enrolment. If genetic screening has taken place as part of routine medical assessments the test may not be repeated, but the result will be reported in the CRF. Participants will be screened to ensure there are no contraÍ²indications for transient immune suppression, in particular: hypertension, diabetes mellitus, tuberculosis, renal impairment, immunocompromised state, osteoporosis, gastric ulceration or severe affective disorder. The study medical monitor should be consulted if the investigator is unsure or to discuss any other screening or eligibility issues. Screening assessments are listed below Í¾and set out under the column headed â€˜Screeningâ€™ in the Trial Assessments Table Ï®, Section Ï±.Ï²Í¿: Ï­. Genetic testing Í¾if no prior result availableÍ¿ Ï®. Medical history and concomitant medication Í¾include prescription medications and overÍ²theÍ²counter preparationsÍ¿ used by the patient from enrolment date, during the study, and at the study drug discontinuation visit will be documented and recorded on eCRF."
31,page_31,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 32 of Ï²Ï´ Ï¯. Physical examination Ï°. Vital signs including blood pressure Ï±. Ocular examination Ï². Visual acuity Ï³. Spectral Domain Optical Coherence Tomography Í¾SDÍ²OCTÍ¿ Ï´. Electrophysiological assessment A letter from the general practitioner detailing the health status of the participant may be requested if the clinician deems it appropriate to confirm eligibility for the trial. These assessments must have been completed within Ïµ months prior to enrolment. In addition, females of childbearing potential will undergo a pregnancy test at screening and again on the day of ATIMP administration. Í·Ç¤ÍµÇ¤Í³Ç¤Í¸Ç¤Íµ Enrolment Participants who fulfil the inclusion criteria based on the results of all screening assessments and pregnancy test will be enrolled in the trial. The ATIMP will be administered within Ïµ months of enrolment. If the ATIMP is not delivered within Ïµ months of enrolment, all screening tests with the exception of genetic testing and electrophysiological assessment will be repeated and eligibility for enrolment reÍ²assessed. Participants who withdraw or are withdrawn from the study for any reason prior to ATIMP administration may be substituted in the study. Í·Ç¤Í¶ IÂÂ–eÂ”Â˜eÂÂ–iÂ‘Â Í·Ç¤Í¶Ç¤Í³ NaÂe aÂd DeÂ•cÂ”iÂ’Â–iÂ‘Â Â‘f IÂÂ˜eÂ•Â–igaÂ–iÂ‘ÂaÂ MediciÂaÂ PÂ”Â‘dÂ—cÂ– AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ is an advanced therapy investigational medicinal product: specifically, a gene therapy product. AAVÏ®Í¬Ï´Í²hGÏ­.Ï³p.coCNGAÏ¯ is a gene transfer agent developed for the treatment of a form of Achromatopsia caused by defects in the gene encoding CNGAÏ¯. This is the alpha subunit of the cGMPÍ²gated ion channel that plays an essential role in the cone phototransduction pathway. Disruption of the gene prevents the conversion of light to an electrical signal, leading to lack of cone function and visual dysfunction. Recombinant adenoÍ²associated virus Í¾rAAVÍ¿ mediated gene transfer of a copy of the normal CNGAÏ¯ gene to the cone photoreceptors, results in stable, long term transgene expression and improves visual function significantly in both rodents and dogs with CNGAÏ¯ gene defects. AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ consists of a linear single strand of DNA packaged in a rAAV protein capsid of serotype Ï´. The AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ genome incorporates Ï®ÏµÏ¬ nucleotides of the wildÍ²type AAVÏ® ITR Í¾Inverted Terminal RepeatsÍ¿ sequences that provide in cis the packaging signal, a cDNA encoding codon optimised human CNGAÏ¯, a human opsin locus control region and green opsin promoter Í¾OPNÏ­MWÍ¿ and a SVÏ°Ï¬ Í¾simian virus Ï°Ï¬Í¿ polyadenylation signal. The icosahedral capsid consists of three related capsid proteins, VPÏ­, VPÏ®, and VPÏ¯. AAV has a compact macromolecular structure and forms stable viral particles Ï®Ï¬nm in diameter. The vector particles are replication incompetent."
32,page_32,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 33 of Ï²Ï´ Í»Ç¤ÍºÇ¤Í·Ç¤Í· ATIMPÂ• ClaÂ•Â•ified aÂ• GeÂeÂ–icallÂ› MÂ‘dified OÂ”gaÂiÂ•ÂÂ• The ATIMP Í¾AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯Í¿ is classified as a genetically modified organism under the Genetically Modified Organisms Í¾Contained UseÍ¿ Regulations Ï®Ï¬Ï¬Ï¬. The Health and Safety Executive Í¾HSEÍ¿ must be notified of each UK clinical trial site administering the ATIMP for first use of premises for genetic modification activities before the activities commence. A risk assessment of the activities has been carried out and has been reviewed by the local Genetic Modification Safety Committee Í¾GMSCÍ¿. Internal approval at site for the GMO activities has been gained. Each clinical trial site administering the ATIMP in the US must obtain local Institutional Biosafety Committee approval to administer recombinant nucleic acid molecule material to human participants. Trial sites that receive support for recombinant or synthetic nucleic acid molecule research from the National Institutes of Health Í¾NIHÍ¿ must register the protocol with the NIH Office of Science Policy Í¾OSPÍ¿ for review prior to initiating trial activities. Í»Ç¤ÍºÇ¤Í·Ç¤Í¸ SÂ‘Â—Â”ce Â‘f ATIMPÂ• The ATIMP has been manufactured at the MeiraGTx II Ltd., ÏµÏ® Britannia Walk, London. NÏ­ Ï³NQ in accordance with current Good Manufacturing Practice for clinical trial materials. The product is released by an EU QP or as per country specific guidelines. Í»Ç¤ÍºÇ¤Í·Ç¤Í¹ PÂ”eÂ’aÂ”aÂ–iÂ‘Â aÂd LabelliÂg Â‘f Â–he IÂÂ˜eÂ•Â–igaÂ–iÂ‘Âal MediciÂal PÂ”Â‘dÂ—cÂ– Preparation and labelling of the investigational medicinal product will be completed in accordance with the relevant GMP guidelines. The ATIMP is a recombinant serotype Ï®Í¬Ï´ adenoÍ²associated viral vector containing a human CNGAÏ¯ cDNA driven by a Ï¬.Ï° kb fragment of the human CAR promoter. US Federal regulations require that a drug should be the subject of an approved marketing application before it is transported or distributed across state lines. As such, in order to ship ATIMP to investigators, the sponsor will submit an IND application in order to obtain an exemption from the FDA with regard to the marketing approval requirement. Í»Ç¤ÍºÇ¤Í·Ç¤Íº DeÂ•cÂ”iÂ’Â–iÂ‘Â aÂd JÂ—Â•Â–ificaÂ–iÂ‘Â Â‘f RÂ‘Â—Â–e Â‘f AdÂiÂiÂ•Â–Â”aÂ–iÂ‘Â aÂd DÂ‘Â•e Efficient transduction of the cone photoreceptor cells requires the ATIMP Í¾rAAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯Í¿ to be administered to the subretinal space. Delivery of vector suspension to the subretinal space will be performed by standard vitrectomy surgery. This will involve a Ï¯Í²port pars plana vitrectomy followed by injection of vector suspension using a fine cannula through small retinotomies into the subretinal space, resulting in a transient retinal detachment. Previous gene therapy clinical trials have shown that the bleb of subretinal vector suspension can be expected to resolve spontaneously over the course of the first Ï®Ï° to Ï°Ï´ hours postoperatively as the fluid is absorbed by the underlying retinal pigment epithelium. Risks to visual function will be minimized by controlling the area of ATIMP delivery, and by leaving the contralateral eye untreated. Injection of fluids under the retina commonly performed delivery of surgical dyes and antithrombotic agents in the management of rhegmatogenous retinal detachment and macular degeneration."
33,page_33,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ï° of Ï²Ï´ The highest ATIMP dose that is intended to be delivered to the trial participants is based on doseÍ²limiting toxicity that was seen in an earlier trial of AAVÏ®Í²mediated gene therapy for LCAÏ®, where Ï­ mL of ATIMP at Ï­ x Ï­Ï¬Ï­Ï® vgÍ¬mL was found to be the highest safe dose that could be administered subretinally. As toxicity in this context is a complex interaction between local retinal effects, wider ocular effects and systemic effects, a conservative decision was taken to use the confirmed safe titre Í¾Ï­ x Ï­Ï¬Ï­Ï® vgÍ¬mLÍ¿, despite using a smaller maximal volume Í¾Ï¬.Ï± mLÍ¿ and thus a slightly lower dose. As AAVÏ®Í¬Ï´Í²mediated transduction of cone photoreceptors in nonÍ²human primates is efficient over a wide range of titres, including much lower titres than used in this study Í¾Vandenberghe et al, Sci Transl Med Ï¯, Ï´Ï´raÏ±Ï°Í¿ we are confident that the CNGAÏ¯ transgene can be delivered to the cones effectively at Ï­ x Ï­Ï¬Ï­Ï® vgÍ¬mL. Í»Ç¤ÍºÇ¤Í·Ç¤Í» NaÂe aÂd DeÂ•cÂ”iÂ’Â–iÂ‘Â Â‘f Each NÂ‘ÂÇ¦IÂÂ˜eÂ•Â–igaÂ–iÂ‘Âal MediciÂal DÂ”Â—g È‹NIMPÈŒ Ï­. Cefuroxime can be administered subconjunctivally at Ï¬.Ï±ml normal saline, or Ï­Ï®Ï±mg in Ï­.Ï¬mL normal saline according to local practice or cefazolin or vancomycin antibiotic given at usual dose at end of surgery Í¾standard dose as prophylaxis for postÍ²operative infectionÍ¿ Ï®. Long acting steroid in the subÍ²tenon space following sclerotomy closure Í¾see details in CNGAÏ¯ ATIMP Management PlanÍ¿. Ï¯. Betamethasone can be administered subconjunctivally at Ï®.mgÍ² Ï±mg in Ï¬.Ï±mL, according to local practice, or dexamethasone can be administered subconjunctivally at Ï­.Ï±mgÍ²Ï®.Ï¬mg in Ï¬.Ï±mL, according to local practice at end of surgery Í¾standard dose as prophylaxis for postÍ²operative inflammationÍ¿ Ï°. Chloramphenicol Ï¬.Ï±Ğ¹ or ofloxacin Í¾topical antibioticÍ¿ Ï° times daily for Ï³ days following ATIMP administration Ï±. Dexamethasone Ï¬.Ï­Ğ¹ Í¾topical steroidÍ¿ or topical prednisolone drops Ï­.Ï¬Ğ¹ should be administered Ï° times daily for Ï° weeks following ATIMP administration Ï° and Ï± above will be administered to minimise inflammation and protect against infection postoperatively. Ï². Omeprazole: x In children aged up to Ï­Ï± weighing Ï± kg to less than Ï­Ï¬ kg Í¾Ï­Ï­ lb to less than Ï®Ï® lbÍ¿: Ï± mg taken once per day x In children aged up to Ï­Ï± weighing Ï­Ï¬ kg to less than Ï®Ï¬ kg Í¾Ï®Ï® lb to less than Ï°Ï° lbÍ¿: Ï­Ï¬ mg taken once per day x In children aged up to Ï­Ï± weighing Ï®Ï¬ kg Í¾Ï°Ï° lbÍ¿ or more: Ï®Ï¬ mg taken once per day Omeprazole will be administered as a gastroÍ²protectant against corticosteroid therapy."
34,page_34,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ï± of Ï²Ï´ Ï³. Prednisolone or Prednisone Í¾oral steroidÍ¿ as prophylaxis against potential intraocular immune responses: Ï¬.Ï± mgÍ¬kg daily for one week prior to ATIMP administration Ï­mgÍ¬kg daily for the first week following ATIMP administration Ï¬.Ï±mgÍ¬kg daily for the second week following ATIMP administration Ï¬.Ï®Ï±mgÍ¬kg daily for the third week following ATIMP administration Ï¬.Ï­Ï®Ï±mgÍ¬kg daily for the fourth week following ATIMP administration All NonÍ² Investigational Medicinal Products Í¾NIMPsÍ¿ are licensed within the EU and US and will be procured from standard hospital stock. Sites will maintain a system that allows adequate reconstruction of NIMP movements and permits recording of which participants received which NIMPs during the trial, with an evaluation of the compliance where necessary. Í·Ç¤Í¶Ç¤Í´ PÂ”Â‘Â–Â‘cÂ‘Â defiÂed cÂiÂicaÂ Â•chedÂ—Âe Í»Ç¤ÍºÇ¤Í¸Ç¤Í· BaÂ•eliÂe AÂ•Â•eÂ•Â•ÂeÂÂ–Â• A detailed assessment of visual function and retinal imaging of both eyes will be performed preoperatively as outlined in Section Ï±.Ï² Í¾Table Ï®: Trial AssessmentsÍ¿. For assessments requiring multiple baselines, testing is preferred on separate days within a maximum ÏµÍ²month period to allow for dayÍ²toÍ²day variation and testÍ²retest variability for individual participants. However, it is acknowledged that a pragmatic balance will be achieved for what is appropriate for the different tests on an individual basis. Each set of baseline measurements may take up to Ï± days to perform in total. Where it is not possible to obtain reliable data for any given baseline assessment, further protocol defined timepoints for those assessments will not be taken, unless required for evaluation of safety. In some instances, results for protocol specified baseline tests may be available as a part of routine clinical examination within Ïµ months. As such, if the subject provides informed consent to use the results from the previously conducted tests, then these assessments will not need to be repeated at baseline. Visual assessment results will be sent for reading and analysis to independent reading centres within the UK and US. For both UK and US sites imaging with OCT, fundus autofluorescence and fundus photography will be reviewed by the site teams but also sent for independent analysis by the Reading Centre, Queens University, Belfast, Ireland, during the course of the trial. Adaptive optics images will be sent to the Medical College of Wisconsin, US, for reading. Octopus perimetry will be sent to the Oregon Health and Science University Casey Eye Institute, US, reading centre. Photoaversion videos will be sent to MeiraGTx and their research development partners. All images will be saved under pseudoÍ²anonymised patient identifiers and surgical images will only be taken of the patientâ€™s eye to ensure that patients remain unidentified. Images and videos obtained during photoaversion testing may reveal some facial characteristics. To the extent possible, images and videos will be anonymised by removing any personally identifiable information from the imaging or video files. Up to Ï­Ï¬ mL of blood will be sampled in order to assess baseline levels of circulating antibodies against AAVÏ´ and of circulating antibodies against rAAV serotype Ï´ so that immunological responses to vector capsids can be determined following ATIMP administration Í¾collectively described as serology in Table"
35,page_35,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ï² of Ï²Ï´ Ï®: Trial AssessmentsÍ¿. We anticipate that that majority of participants will have no detectable preÍ²existing circulating antibodies against AAVÏ´. The presence or absence of circulating antibodies will not affect recruitment of the participant. All serology tests will be performed at a laboratory approved by the sponsor and their research development partners. There is wide variability in the abilities of individual children to perform certain of the proposed investigations; the evaluations for children will be restricted to those tests that individuals are able to perform reliably. Tests that will be performed in all participants are: x Serological tests x Blood pressure x Haematology x Biochemistry x Ocular examination x Colour fundus photography x Spectral Domain Optical coherence tomography Í¾SDÍ²OCTÍ¿ x Fundus Autofluorescence Í¾FAFÍ¿ imaging x Best corrected visual acuity x At least one of static perimetry and Í¬ or fullÍ²field stimulus testing. x LightÍ²sensitivity Í¾PhotoaversionÍ¿ testing Tests that will be performed where possible unless lack of patient coÍ²operation or equipmentÍ¬ facilities are: x Contrast sensitivity x Reading assessment x Colour vision testing x Adaptive optics Í¾AOÍ¿ imaging x QOL questionnaires Further details of clinical assessments can be found in the Gene Therapy for Achromatopsia Í¾CNGAÏ¯Í¿ study manual. Images taken at all timepoints will be sent for independent reading and analysis at centres in both the UK and US. Í¾iÍ¿ Ocular examination and retinal imaging. Ocular examination using slit lamp biomicroscopy will assess the anatomical integrity of the eyes and allow quantification of intraocular inflammation. During the examination, intraocular pressure will be determined by tonometry. Retinal imaging includes colour fundus photography, fundus autofluorescence Í¾FAFÍ¿ imaging, SDÍ²OCT, and adaptive optics Í¾AOÍ¿ imaging. FAF imaging allows visualisation of the retinal pigment epithelium Í¾RPEÍ¿ by taking advantage of its intrinsic fluorescence derived from its lipofuscin content. SDÍ²OCT"
36,page_36,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ï³ of Ï²Ï´ imaging enables measurement of retinal thickness and provides information about the integrity of the layers of the retina. AO imaging provides direct visualization of the photoreceptor mosaics in Ç€iÇ€o. Í¾iiÍ¿ Functional and ParticipantÍ²Related Outcome Assessments. Where possible the participant will complete an age appropriate Impact of Visual Impairment Í¾IVIÍ¿ visionÍ²specific quality of life questionnaire, and EQÏ±DÍ²Ï±L questionnaire and EQÏ±DÍ²Y questionnaire, or equivalent as appropriate. Reading ability including reading acuity, maximum reading rate, and critical print size will be assessed where possible. The degree of light sensitivity Í¾photoaversionÍ¿ will be investigated in two ways Í¾iÍ¿ Objectively by measurement of palpebral aperture narrowing in response to gradually increasing light intensity and Í¾iiÍ¿ Subjectively by participant reported symptomatology. BestÍ²corrected ETDRS visual acuity will be measured in each eye. Contrast sensitivity will be measured using the PelliÍ²Robson chart. Colour vision will be assessed comprehensively using plate tests and computerised tests probing colour discrimination along all Ï¯ axes of colour. Retinal sensitivity will be determined using static perimetry andÍ¬or full field stimulus testing Í¾FSTÍ¿ where possible. FullÍ²field electroretinography Í¾ERGÍ¿ and pattern ERG Í¾PERGÍ¿ will be performed according to the International Society for Clinical Electrophysiology of Vision Í¾ISCEVÍ¿ standards to assess both generalised retinal Í¾rod and cone systemsÍ¿ and isolated macular function. Modified ISCEV protocols may be necessary in young children using internationally recognised modified protocols. For young children, this procedure may be performed under general anaesthesia. ERG data will be analysed and interpreted by dedicated fullÍ²time Clinical Visual Electrophysiology Consultants with extensive experience and who are directly involved in defining ISCEV standards. Í»Ç¤ÍºÇ¤Í¸Ç¤Í¸ ATIMP adÂiÂiÂ•Â–Â”aÂ–iÂ‘Â PÂ”Â‘cedÂ—Â”eÂ• The protocol describes the intended surgical technique for ATIMP administration. The surgical procedure may be modified on a caseÍ²byÍ²case basis in the interests of safety; any modification will be documented in the operation notes and eCRF. Consent to record the surgery will be requested of the participant. Intraocular surgery will be recorded by video via the operating microscope as described in the consent process. Relevant anonymised video recordings and images will be stored alongside the trial database, with the sponsor and held by third party vendors. Í·Ç¤Í¶Ç¤Í´Ç¤Í´Ç¤Í³ PreÇ¦operatiÂ˜e ProcedÂ—res For prophylaxis against potential intraocular immune responses to the ATIMP, participants will be prescribed a course of oral prednisolone as described in section Ï±.Ï°.Ï­.Ï±. Preoperative procedures and intraocular administration of ATIMP will be as described in the Gene Therapy for Achromatopsia Í¾CNGAÏ¯Í¿ study manual."
37,page_37,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ï´ of Ï²Ï´ Í·Ç¤Í¶Ç¤Í´Ç¤Í´Ç¤Í´ TechniqÂ—e for intraocÂ—lar administration of ATIMP The choice of eye for ATIMP administration will be the poorerÍ²seeing eye as identified by the participant and CIÍ¬PI taking into account ocular dominance and visual acuity. The recombinant vector will be delivered in the form of a suspension of viral vector particles injected intraocularly Í¾subretinallyÍ¿ under direct observation using an operating microscope. This procedure will involve a Ï¯Í²port pars plana vitrectomy followed by injection of ATIMP using a fine cannula through small retinotomies into the subretinal space. Surgery will be performed under general anaesthesia. The eye and face will be prepared using povidone iodine solution as per routine intraocular surgery. The face and eye will be covered with an adhesive sterile plastic drape. An opening will be made at the point of the palpebral fissure and a wire speculum inserted to retract the upper and lower eyelids. The speculum and all intraocular instruments will be sterilised according to standard local operating procedures. Three pars plana sclerotomies will be sited to enable intraocular infusion, endoillumination probe and surgical instruments. The fundus will be viewed by means of a binocular indirect ophthalmo microscope Í¾BIOMÍ¿ viewing system or a contact lens. To minimise the possibility of unplanned retinal detachment or preretinal fibrosis, vitrectomy Í¾aspiration of vitreous gelÍ¿ will be performed using a disposable cutter. Intraocular administration of the viral vector suspension Í¾AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯Í¿ will be performed using a subretinal cannula advanced through the retina. Under direct visualisation, the ATIMP will be injected under the neurosensory retina, causing a localised retinal detachment with a selfÍ²sealing nonÍ²expanding retinotomyÍ¬retinotomies. The aim will be to target the ATIMP to the central macula. If appropriate, the bleb of ATIMP will be manipulated to the target area using a fluidÍ²air exchange. The site and extent of the subretinal bleb of ATIMP suspension will be documented by video recording. Following intraocular administration of ATIMP, the retinal periphery will be examined for any unplanned retinal breaks for appropriate management by retinopexy with or without intraocular tamponade at the discretion of the operating surgeon. Intraocular instruments used subsequent to ATIMP delivery are disposable and will be destroyed after a single use. Sclerotomies may be secured using a vicryl suture. Standard doses of cefuroxime antibiotic and betamethasone will be administered subconjunctivally as prophylaxis against postoperative infection and inflammation respectively. Bupivacaine will be administered for analgesia. The surgical procedure may be modified on a caseÍ²byÍ²case basis in the interests of safety; any modification will be documented in the operation notes and CRF. On the basis of our own experience, we anticipate that the subretinal ATIMP bleb will resolve spontaneously during the first Ï°Ï´ hours. Surgery may be performed, as is conventional for intraÍ²ocular procedures, on a dayÍ²case basis and participants will be managed subsequently as outÍ²patients, although hospitalÍ²based accommodation may be used for convenience. Í»Ç¤ÍºÇ¤Í¸Ç¤Í¹ SÂ—bÂ•eÂ“Â—eÂÂ– AÂ•Â•eÂ•Â•ÂeÂÂ–Â• On the first postoperative day a full clinical ocular examination will be performed. In particular, visual acuity, intraocular pressure, the degree of postoperative intraocular inflammation and the area of any"
38,page_38,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e 3Ïµ of Ï²Ï´ residual retinal bleb will be documented. Fundus photography, autofluorescence imaging, ocular examination, intraocular pressure and SDÍ²OCT will be performed at day Ï­ and each subsequent visit post ATIMP administration. A standard postÍ²vitrectomy treatment regimen of topical antibiotic Í¾chloramphenicol Ï¬.Ï±Ğ¹ qds for Ï³ daysÍ¿ and steroid Í¾dexamethasone Ï¬.Ï­Ğ¹ qds for Ï° weeksÍ¿ will be prescribed to minimise inflammation and protect against infection postoperatively. Intraocular pressure of greater than Ï¯Ï¬ mmHg will be managed with topical medication and systemic therapy where indicated, with specialist advice sought as required. Participants will be maintained on oral prednisolone Í¾or other as appropriateÍ¿ for Ï° weeks following administration of ATIMP as described above Í¾Section Ï±.Ï°.Ï®.Ï®.Ï­: PreÍ²operative procedureÍ¿. The possible development of steroidÍ²induced adverse effects will be monitored regularly. In particular, blood pressure will be measured and blood glucose, renal function and liver function will be evaluated through blood biochemistry at the time points specific in Table Ï®: Trial Assessments. Both safety and efficacy of the ATIMP will be evaluated at various time points up to Ï² months after ATIMP delivery. Evaluations will comprise primarily, ocular assessments. The nature and schedule Í¾Section Ï±.Ï²: Trial AssessmentsÍ¿ of these is described below. Í¾iÍ¿ Clinical assessment of intraocular inflammation The degree of intraocular inflammation will be assessed by slitÍ²lamp biomicroscopy at each time point. A temporary intraocular inflammatory response is expected following vitrectomy surgery. This is typically evident clinically on slitÍ²lamp biomicroscopy as â€˜flareâ€™ and cells in the anterior chamber and can be of moderate Í¾Ï®Ğ½ cellsÍ¿ intensity. The degree of intraocular inflammation is expected to decline over the course of the first Ï° weeks following the surgical procedure, at which time the routine topical and systemic immunosuppression will be discontinued. Prolonged or severe intraocular inflammation, or deterioration in visual acuity that may be related to intraocular inflammation, will be investigated and managed conventionally with further topical andÍ¬or systemic immunosuppression. Í¾iiÍ¿ Evaluation of immune responses Up to Ï­Ï¬ mL of blood will be sampled to measure immune response. Antibody responses to AAV capsid proteins will be investigated by ELISA at baseline and at Ï° weeks, Ï¯ months, and Ï² months following ATIMP administration. Í¾iiiÍ¿ Evaluation of biodistribution Systemic biodistribution of vector genomes will be assessed by PCR analysis of tears a compressed cellulose sponge placed under the eye lid until swollenÍ¿, saliva Í¾a minimum of Ï­Ï¬Ï¬ Î¼LÍ¿ and serum Í¾Ï­ mLÍ¿ at Ï­ day and at Ï° weeks following intraocular ATIMP administration. The test will be carried out at a laboratory approved by the sponsor and their research development partners. Í¾ivÍ¿ Assessment of visual function and retinal imaging Assessment of visual function and retinal imaging will be performed as outlined in Section Ï±.Ï² Í¾Trial AssessmentsÍ¿. They will be carried out with the same methods applied for the baseline tests Í¾see"
39,page_39,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°0 of Ï²Ï´ section Ï±.Ï°.Ï®.Ï­ for detailsÍ¿ to allow direct comparison of the data sets. These assessments will be scheduled over a period of a day for visits at day Ï­, day Ï¯, day Ï³, week Ï®, week Ï° and week Ï² after surgery, and up to Ï° days for baseline examinations, and Ï¯ months, Ï² months following ATIMP administration. For day Ï­ and Ï¯ refraction cannot reliably be measured. Therefore, the most recent refraction measurement will be used. All participants will need to be able to perform reliable visual acuity testing and SDÍ²OCT imaging, which are the principal clinical assessments both for safety and efficacy. Other clinical assessments will be undertaken as appropriate for the ability of individual participants, since there is wide variation in the abilities of individual children to perform such tests reliably; the evaluations for individuals may be restricted to those tests that they are able to perform reliably. Additional assessments may be performed if considered appropriate for the management of any unexpected adverse effects. These may be submitted as urgent safety measures and protocol amendments performed where required. Conversely, tests that cannot be reliably performed by a particular participant may be discontinued for that participant. This is not anticipated for the key clinical assessments such as visual acuity test or SDÍ²OCT imaging because participants who are unable to perform such tests will be excluded from the study at the screening phase. Evaluation of safety and efficacy will also be performed on an individual participant basis. We do not anticipate that any discontinuation will affect significantly the overall quality of the safety and efficacy evaluation. Í»Ç¤ÍºÇ¤Í¸Ç¤Íº LabÂ‘Â”aÂ–Â‘Â”Â› PÂ”Â‘cedÂ—Â”eÂ• Blood serum will be processed, to investigate any immune responses to the ATIMP: Ï­. antiÍ²AAVÏ´ neutralising antibodies Ï®. antiÍ²AAVÏ´ antibodies using an ELISA Blood serum, saliva and lacrimal fluid will be processed in the UCL Institute of Ophthalmology to assess dissemination of ATIMP after delivery, where the number of rAAV vector genome copies will be measured using a polymerase chain reaction Í¾PCRÍ¿ approach. Whole blood will be processed at the National Genetics Reference Laboratory in the UK, or a CLIAÍ²accredited molecular diagnostic laboratory in the US, for CNGAÏ¯ mutation screening. Haematology and biochemistry samples and screen will be carried out at the Trust associated laboratories, or an accredited laboratory in the US. Biochemistry and haematology parameters to be analysed are as per the table below: Haematology Biochemistry Haemoglobin Sodium Haematocrit Potassium Erythrocytes Chloride Mean Corpuscular Volume Bilirubin Mean Corpuscular Haemoglobin Alkaline Phosphatase Platelet Aspartate Aminotransferase"
40,page_40,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°1 of Ï²Ï´ Leukocytes Alanine Aminotransferase Absolute Neutrophils Lactate Dehydrogenase Absolute Lymphocytes Gamma Glutamyl Transferase Absolute Neutrophils Protein Absolute Eosinophils Albumin Absolute Basophils Calcium Magnesium Phosphate Urea Urate Creatinine G lucose Í·Ç¤Í¶Ç¤Íµ DiÂ•Â’eÂÂ•iÂg Í»Ç¤ÍºÇ¤Í¹Ç¤Í· ReceiÂ’Â– aÂd SÂ–Â‘Â”age Â‘f Â–he AdÂ˜aÂced TheÂ”aÂ’Â› IÂÂ˜eÂ•Â–igaÂ–iÂ‘Âal MediciÂal PÂ”Â‘dÂ—cÂ– The batch of ATIMP will be stored at either the MeiraGTx II Ltd Manufacturing Facility Í¾MeiraGTx MFÍ¿, or other approved storage facility Í¾details of storage will be specified in the ATIMP Management PlanÍ¿. The product, which is stable at Ñ‡Í´Ï³Ï¬Î£ Celsius, will be stored at Í²Ï³Ï¬Î£ Celsius or below in secure temperature controlled and monitored Í²Ï´Ï¬Î£ Celsius freezers. No further manufacturing or testing will take place at the MeiraGTx MF. Shipping of ATIMP will be on dry ice, accompanied by a temperatureÍ² monitoring device. The ATIMP vector will be dispensed on the same day of administration according to study specific working instructions, with a Ï­Í²hour window for administration after ATIMP has thawed at room temperature. Í·Ç¤Í¶Ç¤Í¶ DÂ‘Â•ageÂ• Í»Ç¤ÍºÇ¤ÍºÇ¤Í· DÂ‘Â•ageÂ• aÂd dÂ‘Â•age ÂÂ‘dificaÂ–iÂ‘ÂÂ• Trial participants will receive a single dose of ATIMP within the range proven to be safe in the preclinical animal studies. These are anticipated to be as described below: Ï­Í¿ low dose Ï®Í¿ intermediate dose Ï¯Í¿ high dose In order to explore optimal dosing within safe limits, additional doses may be administered in order to maximise therapeutic effect, whilst maintaining the safety profile of the product. Any dose that differs from those described above will not exceed the highest titre of . The Chief"
41,page_41,"Gene Therapy for Achromatopsia ( CNGAÏ¯ ) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°2 of Ï²Ï´ Investigator, Medical Monitor and SDMC chair will confirm additional doses in advance of them being administered. The actual titre to be administered will be recorded in the eCRF. The ATIMP will be produced and stored at a titre appropriate for the high dose Í¿ and diluted immediately prior to intraocular administration in Hartmannâ€™s solution at the time of administration for lower doses. The appropriate dilution will be prepared in the operating theatre and this will be checked in by a second individual prior to administration. The check will be recorded in the patientâ€™s source data notes. Further details for doseÍ²escalation criteria are included in Sections Ï°.Ï¯.Ï®. Í·Ç¤Í¶Ç¤Í· AccÂ‘Â—ÂÂ–abiÂiÂ–Â› The ATIMP will be prescribed for a particular participant by one of the investigators and handled according to the ATIMP management plan applicable for each site. A comprehensive ATIMP management plan and associated Working Practices and forms will be in place to ensure that the required accountability and traceability data is collected and retained. Í·Ç¤Í¶Ç¤Í¸ CÂ‘ÂÂ’ÂiaÂce aÂd AdheÂ”eÂce Full compliance is expected since the ATIMP will be surgically delivered by the CI or a delegated vitreoÍ² retinal surgeon. The aim is to target the administered volume into the subretinal space. Any deviation from this will be noted in the CRF. See section Ï±.Ï°.Ï´ Í¾Overdose of trial medicationÍ¿ about the assessment of adherence to the protocol defined delivery of the product. Í·Ç¤Í¶Ç¤Í¹ CÂ‘ÂcÂ‘ÂiÂ–aÂÂ– CaÂ”e Concomitant use of other medications should be avoided unless clinically necessary and should be used with caution, and appropriately documented on study logs where used. All concomitant medications Í¾including steroidsÍ¿ must be recorded in the eCRF from the day of informed consent. Í·Ç¤Í¶Ç¤Íº OÂ˜eÂ”dÂ‘Â•e Â‘f TÂ”iaÂ MedicaÂ–iÂ‘Â Intraocular administration of the ATIMP will be performed by the operating surgeon Í¾CI or a delegated vitreoÍ²retinal surgeonÍ¿. The volume of ATIMP delivered to the target site will be measured from the scale located on syringeÍ¬ plunger and recorded in the CRF. Any overdose will be reported to the sponsor. This is a Phase IÍ¬II exploratory study and the possible impact of any overdose will be considered in the final analysis. Given that this is a single administration study, the trial participant will not be withdrawn but the collected data will be analysed separately in comparison with the data from the participantâ€™s baseline assessments and from other treated participants. Any concern about accurate dosing may warrant suspension of the trial pending appropriate investigation. Overdose of ATIMP may result in development of Adverse Events of various severities that will be recorded and reported as outlined in Section Ï±.Ï­Ï­.Ï¯. Í·Ç¤Í¶Ç¤Í» PÂ”Â‘Â–Â‘cÂ‘Â DiÂ•cÂ‘ÂÂ–iÂÂ—aÂ–iÂ‘Â Í»Ç¤ÍºÇ¤Í¿Ç¤Í· PaÂ”Â–iciÂ’aÂÂ– WiÂ–hdÂ”aÂ™al In consenting to the trial, participants consent to ATIMP administration, trial followÍ²up and data collection."
42,page_42,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°3 of Ï²Ï´ As participation is entirely voluntary, participants may choose to withdraw from the trial at any time without penalty or loss of benefits to which they would otherwise be entitled. Although not obliged to give a reason for withdrawal, a reasonable effort should be made to establish and document this in the withdrawal eCRF, whilst fully respecting the participants rights. Should a participant withdraw from the study, a withdrawal eCRF documenting the reason for withdrawal Í¾if providedÍ¿ will be completed, in addition to the procedures and eCRF for the final visit Í¾Ï² monthÍ¿ assessments, with the participantâ€™s consent. However, participants will be encouraged to participate in any of the planned schedule for the trial whilst arranging a visit for routine Í¾annualÍ¿ clinical followÍ²up. Participants who withdraw prior to ATIMP administration will be regarded as offÍ²protocol and their primary ophthalmologist will resume normal standard of care. Any participant who withdraws prior to administration of ATIMP may be replaced in the study. Participants who withdraw from the study after ATIMP administration will be strongly encouraged to have followÍ²up investigations with their consent, so that the consequences of ATIMP administration can be documented and the data analysed. The CMT may choose to replace a participant who withdraws after ATIMP administration. Í»Ç¤ÍºÇ¤Í¿Ç¤Í¸ TÂ”ial SÂ–Â‘Â’Â’iÂg RÂ—leÂ• The Chief Investigator and Sponsor retain the right to terminate the study. Specific circumstances that may precipitate such termination are as follows: Ï­. Unanticipated severe adverse event in this or other studies indicating a potential health hazard caused by the ATIMP Ï®. Significant protocol deviation and lack of compliance and cooperation on the part of an investigator, which endangers the safety of the participants or the validity of the study Ï¯. Death of a participant at any time point after ATIMP administration that is possibly, probably, or definitely related to the ATIMP Ï°. The occurrence of a nonÍ²ocular malignancy at any point after gene transfer that is possibly, probably, or definitely related to the ATIMP Í·Ç¤Í· OÂ—Â–cÂ‘ÂeÂ• Í·Ç¤Í·Ç¤Í³ PÂ”iÂaÂ”Â› OÂ—Â–cÂ‘ÂeÂ• The primary outcome is defined as any of the below occurring during the Ï² weeks following administration, at least possibly related to the ATIMP, not surgery alone: x Reduction in visual acuity by Ï­Ï± ETDRS letters or more that fails to resolve to within Ï­Ï± letters of baseline in a Ï°Í²week period once prophylactic treatment commences x Severe unresponsive inflammation x Infective endophthalmitis x Ocular malignancy x Grade III or above nonÍ²ocular SUSAR Í¾see section Ï±.Ï­Ï­.Ï¯Í¿"
43,page_43,"Gene Therapy for Achromatopsia (CNGAÏ¯) CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ï° of Ï²Ï´ Í·Ç¤Í·Ç¤Í´ SecÂ‘ÂdaÂ”Â› OÂ—Â–cÂ‘ÂeÂ• The secondary outcomes are measures of the efficacy of the ATIMP; these will be performed on an individual participant basis and will be descriptive in nature. x Any improvements in visual function from baseline that are greater than the baseline variation and are sustained for at least two consecutive assessments. x Any improvement in retinal function from pre Í´ intervention that is greater than the baseline variation and measurable by electrophysiology Í¾pattern ERG or fullÍ²field ERGÍ¿. Quality of life will be measured by the Impact of Visual Impairment Í¾IVIÍ¿ questionnaire and the EQÏ±DÍ²Ï±L and EQÏ±DÍ²Y, or equivalent as appropriate."
44,page_44,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ï± of Ï²Ï´ Í·Ç¤Í¸ TÂ”iaÂ AÂ•Â•eÂ•Â•ÂeÂÂ–Â• Table Ï®: Trial assessments Screening BaselineÏ­, ATIMP admin DÏ­ DÏ¯ WÏ­ WÏ® WÏ° WÏ² WÏ­Ï® WÏ®Ï° Flexibility of schedule Í¾Ğ½ daysÍ¿ Í² Ïµ months Day Ï¬ Ğ½ Ï¬D Ğ½ Ï­D Ğ½ Ï®D Ğ½ Ï°D Ğ½ Ï³D Ğ½ Ï³D Ğ½ Ï­Ï°D Ğ½ Ï­Ï°D Visit number Ï­ Ï® Ï¯ Ï° Ï± Ï² Ï³ Ï´ Ïµ Ï­Ï¬ Ï­Ï­ Ï­Ï® Ï­Ï¯ Informed consent â€¢ Physical exam â€¢ Medical history â€¢ Eligibility determination â€¢ ATIMP administration â˜… Adverse event review â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ Concomitant medication review â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ Genetic screeningÏ® â€¢ Pregnancy test â€¢ â€¢ Vital signsÏ¯ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ HaematologyÏ° â€¢ â€¢ â€¢ â€¢ â€¢ BiochemistryÍ¬glucoseÍ¬liver and renal functionÏ± â€¢ â€¢ â€¢ â€¢ â€¢ Serology â€¢ â€¢ â€¢ â€¢ PCR â€¢ â€¢ QoL questionnaires Í¾IVI and EQÏ±DÍ²Ï±L, or equivalentÍ¿ â€¢ â€¢ Visual acuityÏ² â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ Colour vision assessments â€¢ â€¢ â€¢ â€¢ â€¢ Contrast sensitivity â€¢ â€¢ â€¢ â€¢ â€¢ Reading assessments â€¢ â€¢ â€¢ â€¢ â€¢ Static perimetry â€¢ â€¢ â€¢ â€¢ â€¢ Full Field Stimulus Testing â€¢ â€¢ â€¢ â€¢ â€¢ Ocular examination â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢"
45,page_45,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ï² of Ï²Ï´ Screening BaselineÏ­, ATIMP admin DÏ­ DÏ¯ WÏ­ WÏ® WÏ° WÏ² WÏ­Ï® WÏ®Ï° Flexibility of schedule Í¾Ğ½ daysÍ¿ Í² Ïµ months Day Ï¬ Ğ½ Ï¬D Ğ½ Ï­D Ğ½ Ï®D Ğ½ Ï°D Ğ½ Ï³D Ğ½ Ï³D Ğ½ Ï­Ï°D Ğ½ Ï­Ï°D Fundus photography â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ Optical coherence tomography â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ Adaptive optics imaging â€¢ â€¢ â€¢ Fundus autofluorescence â€¢ â€¢ â€¢ â€¢ Pattern Electroretinography,Ï³ â€¢ â€¢ Full field ElectroretinographyÏ³ â€¢ â€¢ PhotoaversionÍ¬ light sensitivity assessments Í¾test and questionnairesÍ¿ â€¢Ï´ â€¢Ï´ â€¢Ï´ â€¢Ïµ â€¢Ïµ Ï­ Baseline assessments may be performed on the same day where considered logistically and clinically appropriate Ï® If result is available from prior testing, no repeat test mandated. Result will be reported into the CRF. 3 Measurements for vital signs include: blood pressure, pulse, respiration rate, arterial oxygen saturation, temperature, height and weight Ï° Hematology to include the following parameters: Haemoglobin, Haematocrit, Erythrocytes, Mean Corpuscular Volume, Mean Corpuscular Haemoglobin, Platelet, Leukocytes, Absolute Neutrophils, Absolute Lymphocytes, Absolute Neutrophils, Absolute Eosinophils, Absolute Basophils Ï± Biochemistry to include the following parameters: Sodium, Potassium, Chloride, Bilirubin, Alkaline Phosphatase, Aspartate Aminotransferase, Alanine, Aminotransferase, Lactate Dehydrogenase, Gamma Glutamyl Transferase, Total Protein, Albumin, Calcium, Magnesium, Phosphate, UreaÍ¬BUN, Urate, Creatinine, Glucose Ï² Visual acuity at day Ï­ and Ï¯ will be assessed using the previous refraction. Ï³ ERG assessments may be performed under general anaesthesia if necessary. Ï´ Photoaversion Questionnaire only to be completed at one baseline visit, â€œPhotoaversion Device Questionnaire Í´ Baselineâ€ to be completed after every PA assessment Ïµ â€œPhotoaversion Device Questionnaire Í´ after Surgeryâ€ to be used at week Ï­Ï® and week Ï®Ï° straight after Photoaversion assessments. For management of visits delayed due to COVID_1Ïµ refer to appendix."
46,page_46,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ï³ of Ï²Ï´ Í·Ç¤Í¸Ç¤Í³ EaÂ”ÂÂ› SÂ–Â‘Â’Â’iÂg Â‘f FÂ‘ÂÂÂ‘Â™Ç¦Â—Â’ If a participant chooses to discontinue their trial treatment, they should continue to be followed up as closely as possible to the followÍ²up schedule defined in the protocol, providing they are willing. If, however, the participant exercises the view that they no longer wish to be followed up either, this view must be respected, and the participant withdrawn entirely from the trial. MeiraGTx UK II Ltd. should be informed of the withdrawal. Data already collected will be kept and included in analyses according to the intentionÍ²toÍ²treat principle for all participants who stop follow up early. Participants who stop trial followÍ²up early may be replaced. Í·Ç¤Í¸Ç¤Í´ LÂ‘Â•Â• Â–Â‘ FÂ‘ÂÂÂ‘Â™Ç¦Â—Â’ This is a highly motivated patient group who are likely to remain committed to the research. Continued follow up of all participants will be strongly encouraged whilst being mindful of the importance of ensuring the autonomy of participants in regard to their treatment decisions and willingness to continue to participate in the trial. Í·Ç¤Í¸Ç¤Íµ TÂ”iaÂ CÂÂ‘Â•Â—Â”e The end of the entire trial is considered the last followÍ²up visit of the last participant. For each participant, the trial will terminate at the last scheduled visit Ï² months following ATIMP administration. The MHRA and FDA will be notified of the end of the trial within ÏµÏ¬ days of its completion. Í·Ç¤Í¸Ç¤Í¶ LÂ‘Âg TeÂ”Â FÂ‘ÂÂÂ‘Â™Ç¦UÂ’ AfÂ–eÂ” Â–he EÂd Â‘f Â–he TÂ”iaÂ At the end of this trial, participants will be invited to enrol in a followÍ²up study to determine the longerÍ²term safety and efficacy up to Ï²Ï¬ monthsâ€™ post treatment administration. Í·Ç¤Í¹ SaÂÂ’Âe SiÂœe This is a Phase IÍ¬II dose escalation trial to establish safety and assess indicators of potential efficacy of the ATIMP, therefore there is no formal sample size calculation. The trial will enrol up to Ï­Ï´ participants, as described in section Ï°.Ï¯.Ï®.Ï®. The limited number of participants is necessitated by the rare nature of the disease under investigation. The information obtained in this dose escalation study will help inform the design of a future Phase ll interventional study. Í·Ç¤Íº RecÂ”Â—iÂ–ÂeÂÂ– aÂd ReÂ–eÂÂ–iÂ‘Â Í·Ç¤ÍºÇ¤Í³ RecÂ”Â—iÂ–ÂeÂÂ– Most participants will be recruited through Moorfields Eye Hospital, UK, or the Kellogg Eye Centre, US, or on referral by ophthalmologists within or outside the UK or US. Members of their direct clinical care team will approach potential participants in the first instance to discuss whether they would like to consider participating. Potential participants may also contact the trial team independently. We expect to recruit up to Ï­Ï´ participants in this dose escalation study. Í·Ç¤ÍºÇ¤Í´ ReÂ–eÂÂ–iÂ‘Â Participants will be supported to remain in followÍ²up by regular contact as per the protocol, provision of a Ï®Ï°Í²hour hotline to a member of the trial team."
47,page_47,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ï´ of Ï²Ï´ Í·Ç¤Í» AÂ•Â•igÂÂeÂÂ– Â‘f IÂÂ–eÂ”Â˜eÂÂ–iÂ‘Â Í·Ç¤Í»Ç¤Í³ AÂÂÂ‘caÂ–iÂ‘Â All participants will receive the same intervention in this open label, nonÍ²randomised trial: subretinal administration of AAVÏ´Í²hGÏ­.Ï³p.coCNGAÏ¯ to one eye. The dose received by each participant will depend on the timeÍ¬order of their enrolment in the trial according to the sequence of dose escalation, and the extent of dose limiting events Í¾see sections Ï°.Ï¯.Ï® and Ï±.Ï°.Ï° for dose escalation informationÍ¿. Í·Ç¤Í³Í² DaÂ–a CÂ‘ÂÂecÂ–iÂ‘ÂÇ¡ MaÂageÂeÂÂ– aÂd AÂaÂÂ›Â•iÂ• Í·Ç¤Í³Í²Ç¤Í³ DaÂ–a cÂ‘ÂÂecÂ–iÂ‘ÂÇ¡ ÂaÂageÂeÂÂ– aÂd eÂÂ–Â”Â› Syne qua non will be responsible for data management activities for the study. Data will be captured in a fully validated, Ï®Ï­ CFR Part Ï­Ï­ compliant Electronic Data Capture Í¾EDCÍ¿ system. Authorised site staff with access to the EDC system following system training and a successful competency assessment. Data required by the protocol will first be recorded on source documents Í¾e.g. medical records and studyÍ²specific data capture tools as neededÍ¿ and then entered by site staff into the EDC system. All information in EDC must be traceable to these source documents. Any data recorded directly into EDC will be defined prior to the start of data collection. All data is currently anticipated to be associated with source data records. Data validation checks will be activated during data entry to identify data discrepancies. Appropriate error messages will be displayed to allow modification or verification of data by the site staff. Monitoring staff will review the data for completeness and accuracy, instructing site staff to make any required corrections or additions via data queries. Data Management will run further automated validation checks and review the data, raising further data queries to the sites for resolution of any inconsistencies. The Investigator will review the eCRFs for completeness and accuracy then electronically approve the data, retaining full responsibility for its accuracy and authenticity. Medical history and adverse events will be coded using the Medical Dictionary for Regulatory Activities Í¾MedDRAÍ¿ terminology. Prior and concomitant medication will be coded using the World Health Organization Drug Í¾WHOÍ¿Í²Drug Dictionary which employs the Anatomical Therapeutic Chemical Í¾ATCÍ¿ classification system. Further coding details and data management processes will be described in a Data Management Plan Í¾DMPÍ¿. All actions within the EDC system are captured within an audit trail. After all data, have been entered, validated and signed off, the database will be locked."
48,page_48,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï°Ïµ of Ï²Ï´ At the end of the study, PDF copies of the eCRFs for each subject and supporting information will be provided to sites and the Sponsor. The electronic data will be provided to the Sponsor. Í·Ç¤Í³Í²Ç¤Í´ NÂ‘ÂÇ¦AdheÂ”eÂce aÂd NÂ‘ÂÇ¦ReÂ–eÂÂ–iÂ‘Â Participants who withdraw from the trial after the intervention will be encouraged to participate in any of the planned followÍ²up scheduled for the trial with their consent. Data collected prior to withdrawal will be considered in the interpretation of results. Reasons for withdrawal from the trial will be documented on a withdrawal CRF where possible, in addition to the procedures and CRF for the final visit Í¾Ï² monthÍ¿ assessments with the participantâ€™s consent. Í·Ç¤Í³Í²Ç¤Íµ SÂ–aÂ–iÂ•Â–icaÂ MeÂ–hÂ‘dÂ• Í»Ç¤Í·Í¶Ç¤Í¹Ç¤Í· SÂ–aÂ–iÂ•Â–ical AÂalÂ›Â•iÂ• PlaÂ A formal Statistical Analysis Plan Í¾SAPÍ¿ will be approved by the sponsor. This trial is an open label, no crossover, phase IÍ¬II trial involving a small number of participants, and analysis of the primary and secondary outcomes will be descriptive in nature. Í»Ç¤Í·Í¶Ç¤Í¹Ç¤Í¸ SÂ–aÂ–iÂ•Â–ical MeÂ–hÂ‘dÂ• È‚ PÂ”iÂaÂ”Â› OÂ—Â–cÂ‘Âe AÂalÂ›Â•iÂ• The primary outcome is safety of subretinal administration of the ATIMP defined as any of the below occurring during the Ï² weeks following administration, at least possibly related to the ATIMP, not surgery alone: x Reduction in visual acuity by Ï­Ï± ETDRS letters or more that fails to resolve to within Ï­Ï± letters of baseline in a Ï°Í²week period once prophylactic treatment commences x Severe unresponsive inflammation x Infective endophthalmitis x Ocular malignancy x Grade III or above nonÍ²ocular SUSAR Í¾see section Ï±.Ï­Ï­.Ï¯Í¿ The number of DLEs at each dose level will be summarised by cohort and overall. It is anticipated that the ATIMP will be administered at the MTD in up to Ï­Ï´ participants. Safety data relating to these participants will allow estimation of an upper bound for the true event rate through a ÏµÏ±Ğ¹ confidence interval. Í»Ç¤Í·Í¶Ç¤Í¹Ç¤Í¹ SÂ–aÂ–iÂ•Â–ical MeÂ–hÂ‘dÂ• È‚ SecÂ‘ÂdaÂ”Â› OÂ—Â–cÂ‘Âe AÂalÂ›Â•iÂ• The secondary outcomes are measures of the efficacy of the ATIMP; these will be performed on an individual participant basis and will be primarily descriptive in nature. Standard assessments will be used to measure visual function and established methods of analysis, appropriate for the assessment will be used to evaluate the data. For specialist assessments, data will be analysed by the expert team memberÍ¾sÍ¿ who developed the assessment. Final data will be reported descriptively. Efficacy will be indicated by: Ï­Í¿ Any improvement in visual function from baseline that is greater than the baseline variation for that test and is sustained for at least two consecutive assessments."
49,page_49,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±0 of Ï²Ï´ Ï®Í¿ Any improvement in retinal function from pre Í´ intervention assessment that is greater than baseline variation and measurable by electrophysiology Í¾pattern ERG or fullÍ²field ERGÍ¿. Measures will be reported individually and aggregated across participants as the proportion who satisfy the above criteria. Quality of life patient reported outcome measures will be used to correlate a participantâ€™s feeling about their own wellbeing with clinical observations. Í»Ç¤Í·Í¶Ç¤Í¹Ç¤Íº SÂ–aÂ–iÂ•Â–ical MeÂ–hÂ‘dÂ• È‚ HealÂ–h EcÂ‘ÂÂ‘ÂicÂ• AÂalÂ›Â•iÂ• No health economic evaluation is planned, but the collection of EQÏ±D would allow Quality Adjusted Life Years Í¾QALYsÍ¿ to be calculated. Í·Ç¤Í³Í³ DaÂ–a MÂ‘ÂiÂ–Â‘Â”iÂg Í·Ç¤Í³Í³Ç¤Í³ SafeÂ–Â› DaÂ–a MÂ‘ÂiÂ–Â‘Â”iÂg CÂ‘ÂÂiÂ–Â–ee To ensure the safety and efficacy and overall trial conduct, an SDMC will be established and take part in the data monitoring. The SDMC will consist of an independent consultant in pharmaceutical medicine who will be supported by the medical monitor, principal investigator and medical retina expert, and other independent uveitis or medical experts as required. The SDMC will make recommendations on the safety data prior to any dose changes. Further details of the roles and responsibilities of the SDMC, including membership, decision making processes Í¾and description of stopping rules andÍ¬or guidelines where applicableÍ¿ are described in detail in the CNGAÏ¯ Gene Therapy Trial for Achromatopsia SDMC Charter. Í·Ç¤Í³Í³Ç¤Í´ IÂÂ–eÂ”iÂ AÂaÂÂ›Â•eÂ• No formal interim analysis is planned within the trial, but periodic reports concerning participant safety and key efficacy outcomes will be prepared for the SDMC as agreed in the SDMC charter. Í·Ç¤Í³Í³Ç¤Íµ DaÂ–a MÂ‘ÂiÂ–Â‘Â”iÂg fÂ‘Â” HaÂ”Â Í»Ç¤Í·Í·Ç¤Í¹Ç¤Í· SafeÂ–Â› Â”eÂ’Â‘Â”Â–iÂg Pharmacovigilance services will be delegated to an appropriately qualified and evaluated service provider. Definitions of harm of the EU Directive Ï®Ï¬Ï¬Ï­Í¬Ï®Ï¬Í¬EC Article Ï® based on the principles of ICH GCP apply to this trial."
50,page_50,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±1 of Ï²Ï´ Table Ï¯: Adverse Event Definitions Adverse Event (AE) Any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this product. Adverse Reaction (AR) Any untoward and unintended response to an investigational medicinal product related to any dose administered This inclÆµdes medication errorsÍ• Æµses oÆµtside of protocol Í¾inclÆµding misÆµse and abÆµse of prodÆµctÍ¿ Unexpected Adverse Reaction (UAR) An adverse reaction, the nature or severity of which is not consistent with the applicable product information Í¾eg Investigatorâ€™s Brochure for an unauthorised product or summary of product characteristics Í¾SPCÍ¿ for an authorised product. Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) Any AE or AR that at any dose: x results in death x is life threateningÎ x requires hospitalisation or prolongs existing hospitalisationÎÎ x results in persistent or significant disability or incapacity x is a congenital anomaly or birth defect x or is another important medical conditionÎÎÎ SUSAR Suspected Unexpected Serious Adverse Reaction Î the term life threatening here refers to an event in which the participant is at risk of death at the time of the event; it does not refer to an event that might hypothetically cause death if it was more severe Í¾e.g., a silent myocardial infarctionÍ¿ ÎÎ Hospitalisation is defined as an inÍ²patient admission, regardless of length of stay, even if the hospitalisation is a precautionary measure for continued observation. Hospitalisation for preÍ²existing conditions Í¾including elective procedures that have not worsenedÍ¿ do not constitute an SAE ÎÎÎ Medical judgement should be exercised in deciding whether an AE or AR is serious in other situations. Important AEs or ARs that may not be immediately life threatening or result in death or hospitalisation but may seriously jeopardise the participant by requiring intervention to prevent one of the other outcomes listed in the table Í¾e.g., a secondary malignancy, an allergic bronchospasm requiring intensive emergency treatment, seizures or blood dyscrasias that do not require hospitalisation, or development of drug dependencyÍ¿. Adverse events include: x an exacerbation of a preÍ²existing illness x an increase in the frequency or intensity of a preÍ²existing episodic event or condition x a condition Í¾regardless of whether PRESENT prior to the start of the trialÍ¿ that is DETECTED after trial drug administration. Í¾This does not include preÍ²existing conditions recorded as such at baseline Í´ as they are not detected after trial drug administration.Í¿ x continuous persistent disease or a symptom present at baseline that worsens following ATIMP administration"
51,page_51,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±2 of Ï²Ï´ Adverse events do NOT include: x Medical or surgical procedures: the condition that leads to the procedure is the adverse event x PreÍ²existing disease or a condition present before ATIMP administration that does not worsen x Hospitalisation where no untoward or unintended response has occurred e.g. elective cosmetic surgery x Overdose of medication without signs or symptoms Í»Ç¤Í·Í·Ç¤Í¹Ç¤Í¸ OÂ–heÂ” NÂ‘Â–ifiable AdÂ˜eÂ”Â•e EÂ˜eÂÂ–Â• In order to manage the safety risks associated with administration of the ATIMP, all safety events will be reviewed within a short time frame for all participants, as described in the CNGAÏ¯ Gene Therapy Trial for Achromatopsia Data Management Plan. Pregnancy is the only additional notifiable event that requires expedited reporting. Í»Ç¤Í·Í·Ç¤Í¹Ç¤Í¹ PÂ”Â‘cedÂ—Â”eÂ• Â–Â‘ fÂ‘llÂ‘Â™ iÂ Â–he eÂ˜eÂÂ– Â‘f feÂale Â’aÂ”Â–iciÂ’aÂÂ–Â• becÂ‘ÂiÂg Â’Â”egÂaÂÂ– A pregnancy test will be conducted for all females of childbearing age who are sexually active, and the results will be recorded in the medical notes before enrolling a volunteer to the trial. Females with a positive pregnancy test at this point will be excluded from the trial. Where appropriate, a further pregnancy test will be performed on the day of administration of the ATIMP. Female participants with a positive pregnancy test at this point will be excluded from the trial prior to administration of the ATIMP. Although participants are instructed to use double barrier contraception, we cannot exclude entirely that a participant might become pregnant after administration of the ATIMP. In the unlikely event that a participant is found to be pregnant we will notify their GP that she is participating in a gene therapy trial and that, although the risks involved are minimal, there is a chance of gene transfer to the unborn child. With the participantâ€™s consent, we will ask the GPÍ¬obstetrician to provide us with regular reports about the pregnancy until delivery. The pregnancy will be reported to the pharmacovigilance service provider on a pregnancy report form within Ï®Ï° hours of the investigator becoming aware of the event. The participant will continue to be assessed until outcome of the pregnancy. However, if the participant is unable or unwilling to participate further in the trial, she will be encouraged to continue clinical monitoring visits to assess ocular health. In this situation, we may choose to enrol another participant to ensure the scientific validity of the trial. Í»Ç¤Í·Í·Ç¤Í¹Ç¤Íº PÂ”Â‘cedÂ—Â”eÂ• Â–Â‘ fÂ‘llÂ‘Â™ iÂ Â–he eÂ˜eÂÂ– Â‘f Â–he Â’aÂ”Â–ÂeÂ”Â• Â‘f Âale Â’aÂ”Â–iciÂ’aÂÂ–Â• becÂ‘ÂiÂg Â’Â”egÂaÂÂ– Although participants are instructed to use double barrier contraception, we cannot exclude entirely that the partner of a participant might become pregnant after administration of the ATIMP. In the unlikely event that this occurs we will notify the participantâ€™s GP that he is participating in a gene therapy trial and that, although the risks involved are minimal, there is a chance of gene transfer to the unborn child. With the participantâ€™s consent, we will request the partner to contact us to ascertain the status of the pregnancy and the outcome. The pregnancy will be reported to PV Service Provider on a pregnancy report form within Ï®Ï° hours of the investigator becoming aware of the event."
52,page_52,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±3 of Ï²Ï´ Í»Ç¤Í·Í·Ç¤Í¹Ç¤Í» IÂÂ˜eÂ•Â–igaÂ–Â‘Â” Â”eÂ•Â’Â‘ÂÂ•ibiliÂ–ieÂ• Â”elaÂ–iÂg Â–Â‘ Â•afeÂ–Â› Â”eÂ’Â‘Â”Â–iÂg The Investigator will assume overall responsibility for evaluating and reporting adverse events. In urgent situations, a member of the trial team may report on their behalf, while making every effort to discuss the event with them. The investigator may consult the study medical monitor for advice, but they will assume overall responsibility for the evaluation, assignment of clinical significance and reporting of adverse events. All nonÍ²serious AEs and ARs, whether expected or not, should be recorded in the participantâ€™s medical notes, including all events observed following ATIMP administration, and in the eCRF. These should be entered on to the database according to the timelines defined in the CNGAÏ¯ Gene Therapy trial for Achromatopsia Data Management Plan to allow appropriate monitoring by the CMT. SAEs and SARs should be notified to PV Service Provider immediately the investigator becomes aware of the event Í¾in no circumstance should this notification take longer than Ï®Ï° hoursÍ¿. Clinically significant abnormalities in the results of objective tests will also be recorded as adverse events. If the results are not expected as part of disease or surgery these will also be recorded as unexpected. There are currently no expected events associated with the ATIMP. All serious adverse events will be recorded in the hospital notes and the eCRF. Adverse events will be recorded with clinical symptoms and accompanied with a simple, brief description of the event, including dates as appropriate. All adverse events will be recorded until the end of the trial Í¾refer to Section Ï±.Ï².Ï¯ for definitionÍ¿, or until pregnancy outcome in the case of pregnancy. All SAEs will be recorded, fully investigated and appropriately managed until resolution or stabilisation and CI sign off. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í·Ç¤Í³ SerioÂ—sness assessment When an AE or AR occurs, the investigator responsible for the care of the participant must first assess whether or not the event is serious using the definition given in Table Ï¯. If the event is classified as â€˜seriousâ€™ an SAE form must be completed and emailed to PV Service Provider Í¾or delegated bodyÍ¿ notified within Ï®Ï° hours of the investigator becoming aware of the event. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í·Ç¤Í´ SeÂ˜eritÂ› or grading of AdÂ˜erse EÂ˜ents The severity of all AEs andÍ¬or ARs Í¾serious and nonÍ²seriousÍ¿ in this trial should be graded using the toxicity grading in NIH CTCAE Version Ï±.Ï¬ Í¾NIH, Ï®Ï¬Ï­Ï´Í¿. Table Ï°: Grading of Adverse Events Category Definition Mild (Grade I) Asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Moderate (Grade II) Minimal, local or nonÍ²invasive intervention indicated; limiting age appropriate instrumental ADLÎ Severe (Grade III) Severe or medically significant but not immediately life threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting selfÍ²care ADLÎÎ Grade IV Life threatening consequences; urgent intervention indicated Grade V Death related to AE Î Instrumental ADL Í¾Activities of Daily LivingÍ¿ refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc"
53,page_53,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ï° of Ï²Ï´ ÎÎSelfÍ²care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í·Ç¤Íµ CaÂ—salitÂ› Causality will be assessed in terms of both the ATIMP and the surgical procedures. Based on all available information at the time of completion of the case report form, the investigator must assess the causality of all serious events or reactions. It is of importance in this trial to capture and differentiate events related to: x The ATIMP administration surgery x The ATIMP The differentiated causality assessments will be captured in the trial specific CRF and SAE form. If the event is related to the ATIMP, definitions in Table Ï± will be used to capture the information. Any event that is only related to the ATIMP administration surgery will be classified as an Adverse Event. The study medical monitor is available Ï®Ï°Í¬Ï³ to provide any advice as required Table Ï±: Causality definitions Relationship Description Event Type Unrelated There is no evidence of any causal relationship Unrelated SAE Unlikely to be related There is little evidence to suggest that there is a causal relationship Í¾e.g., the event did not occur within a reasonable time after administration of the trial medicationÍ¿. There is another reasonable explanation for the event Í¾e.g., the participantâ€™s clinical condition or other concomitant treatmentÍ¿ Unrelated SAE Possibly related There is some evidence to suggest a causal relationship Í¾e.g., because the event occurs within a reasonable time after administration of the trial medicationÍ¿. However, the influence of other factors may have contributed to the event Í¾e.g., the participantâ€™s clinical condition or other concomitant treatmentÍ¿ SAR Probably related There is evidence to suggest a causal relationship and the influence of other factors is unlikely SAR Definitely related There is clear evidence to suggest a causal relationship and other possible contributing factors can be ruled out. SAR Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í·Ç¤Í¶ EÂšpectedness In view of the very limited clinical experience with the ATIMP there are at present no events considered as expected for the ATIMP. Therefore, any SAEs that are related to the ATIMP Í¾i.e., considered a SARÍ¿ will be deemed a SUSAR Í¾suspected, unexpected, serious adverse reactionÍ¿ and MHRA, RECÍ¬IBC, FDA, and NIH reporting guidelines apply Í¾see Notifications sections of the protocolÍ¿."
54,page_54,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ï± of Ï²Ï´ Table Ï²: Assessment of expectedness Category Definition Expected An adverse event that is classed in nature as serious and which is consistent with the information about the surgery listed in the Investigator Brochure or clearly defined in the protocol. In view of the very limited clinical experience with the ATIMP there are at present no events considered as expected for the ATIMP listed in the current Investigator Brochure. Unexpected An adverse event that is classed in nature as serious and which is not consistent with the information about the ATIMP and surgery listed in the Investigator BrochureÎ or clearly defined in the protocol. ÎThis includes listed events that are more frequently reported or more severe than previously reported The reference document to be used to assess expectedness against ATIMP and surgery is the Investigator Brochure. ProcedureÍ²related adverse events cannot be considered expected to the ATIMP. Previous experience with AAVÍ²mediated gene therapy in the retina indicates that the risks are largely limited to the eye. A temporary andÍ¬or mild decrease in visual acuity, due to detachment of the retina or postÍ²surgical inflammation, is to be expected after intraocular surgery and is not expected to cause undue discomfort. Therefore, we have defined the success criteria for the primary outcome Í¾safetyÍ¿ as the absence of an adverse event that has a substantial and sustained negative impact on vision, as well as the absence of any nonÍ²ocular SUSAR. Expected events associated with surgery: x Temporary andÍ¬or mild decrease in visual acuity Í¾to hand movements or better for a period of up to Ï´ weeksÍ¿, due to detachment of the retina or postÍ²surgical inflammation x Ocular discomfort x Epiphora x Periocular swelling x Diplopia x Ptosis x Subconjunctival or intraocular haemorrhage x Corneal abrasion x Retinal tear or detachment x Wound leak x Ocular hypotony or raised intraocular pressure x Overfill or underfill of any intraocular gas tamponade x Mild intraÍ² or extraÍ²ocular inflammation x Scleral or conjunctival suture granuloma x Lens opacity or dislocation x Systemic adverse events related to sedation or general anaesthesia, including nerve or vascular injury"
55,page_55,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ï² of Ï²Ï´ Í»Ç¤Í·Í·Ç¤Í¹Ç¤Í¼ NÂ‘Â–ificaÂ–iÂ‘ÂÂ• Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í¸Ç¤Í³ Notifications bÂ› the InÂ˜estigator to PharmacoÂ˜igilance All adverse events will be recorded in the hospital notes and the eCRF from the date of written informed consent until last study visit. Investigators should notify PV service provider of any SAEs and SARs occurring during this period. After the last visit, any SAE reported to the investigator and considered causally related to trial treatment should be reported as part of the follow up study. For any participants that do not go into the follow up study, then SAEs that occur after the end of the trial and that may be attributed to ATIMP administration should be reported to the relevant regulatory agencies. PV service provider must be notified of all SAEs and SARs within Ï®Ï° hours of the investigator becoming aware of the event. The investigator will respond to any SAE queries raised by PV service provider as soon as possible. The SAE form must be completed by the investigator Í¾the consultant named on the delegation of responsibilities list who is responsible for the participantâ€™s careÍ¿ with attention paid to the grading and causality of the event. In the absence of the responsible investigator, the SAE form should be completed and signed by a member of the site trial team and emailed as appropriate within the timeline. The responsible investigator should check the SAE form at the earliest opportunity, make any changes necessary, sign and then email to PV service provider. Systems will be in place at the site to enable the investigator to check the form for clinical accuracy as soon as possible. The minimum criteria required for reporting an SAE are:Í² x the trial number x Participant number x date of birth x name of reporting investigator, and x sufficient information on the event to confirm seriousness. Any further information regarding the event that is unavailable at the time of the first report should be sent as soon as it becomes available. Participants must be followed up until clinical recovery is complete and laboratory results have returned to normal or baseline values, or until the event has stabilised. FollowÍ²up should continue after completion of trial followÍ²up Í¾i.e. Ï² months after delivery of ATIMPÍ¿ if necessary. FollowÍ²up SAE forms Í¾clearly marked as followÍ²upÍ¿ should be completed and emailed to PV service provider as further information becomes available. Additional information andÍ¬or copies of test results etc may be provided separately. The participant must be identified by trial number, participant number and date of birth only. The participantâ€™s name should not be used on any correspondence and should be blacked out and replaced with trial identifiers on any test results if it is displayed. Such instances must also be reported as per appropriate SOP. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í¸Ç¤Í´ Reporting Urgent SafetÂ› MeasÂ—res MeiraGTx UK II Ltd. or investigator may take appropriate urgent safety measures in order to protect research participants against any immediate hazard to their health or safety."
56,page_56,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ï³ of Ï²Ï´ If any urgent safety measures are taken the CIÍ¬PIÍ¬ MeiraGTx UK II Ltd. shall immediately Í¾no later than Ï¯ days from the date the measures are takenÍ¿, give written notice as per local reporting requirements of the measures taken and the circumstances giving rise to those measures, according to the relevant SOP. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í¸Ç¤Íµ PV SerÂ˜ice ProÂ˜ider responsibilities PV service provider will follow PV service provider Standard Operating Procedures and a study specific Safety Management Plan to ensure that case processing of events occurs within appropriate regulatory timeframes. PV service provider will submit Development Safety Update Reports Í¾DSURsÍ¿ to regulatory authorities. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í¸Ç¤Í¶ Reporting SUSARs in International Trials The mechanism for reporting SUSARs that occur outside of the UK to the MHRA, and those that occur outside of the US to the FDA will be covered in the trial specific Safety Management Plan. Í·Ç¤Í³Í³Ç¤ÍµÇ¤Í¸Ç¤Í· AnnÂ—al Progress Reports An annual progress report Í¾APRÍ¿ will be submitted to the REC within Ï¯Ï¬ days of the anniversary date on which the favourable opinion was given, and annually until the trial is declared ended. Annual IRB applications for continuing review will be submitted with sufficient time to allow review and approval of trial continuation. Í·Ç¤Í³Í³Ç¤Í¶ QÂ—aÂiÂ–Â› AÂ•Â•Â—Â”aÂce aÂd CÂ‘ÂÂ–Â”Â‘Â Í»Ç¤Í·Í·Ç¤ÍºÇ¤Í· RiÂ•k AÂ•Â•eÂ•Â•ÂeÂÂ– The Quality Assurance Í¾QAÍ¿ and Quality Control Í¾QCÍ¿ considerations for the CNGAÏ¯ Gene Therapy trial for Achromatopsia are based on MeiraGTx UK II Ltd. Quality Management Policy that includes a formal Risk Assessment, and that acknowledges the risks associated with the conduct of the trial and proposals of how to mitigate them through appropriate QA and QC processes. Risks are defined in terms of their impact on: the rights and safety of participants; project concept including trial design, reliability of results and institutional risk; project management; and other considerations. Í»Ç¤Í·Í·Ç¤ÍºÇ¤Í¸ CliÂical MÂ‘ÂiÂ–Â‘Â”iÂg The frequency, type and intensity of routine and triggered onÍ²site monitoring will be detailed in the trial Monitoring Plan Í¾MPÍ¿. The MP will also detail the procedures for review and signÍ²off of monitoring reports. In the event of a request for a trial site inspection by any regulatory authority MeiraGTx UK II Ltd. must be notified as soon as possible. Í»Ç¤Í·Í·Ç¤ÍºÇ¤Í¹ DiÂ”ecÂ– acceÂ•Â• Â–Â‘ Â’aÂ”Â–iciÂ’aÂÂ– Â”ecÂ‘Â”dÂ• Participating investigators must agree to allow trial related monitoring, including audits, REC review and regulatory inspections, by providing access to source data and other trial related documentation as required. Participant consent for this must be obtained as part of the informed consent process for the trial. Í»Ç¤Í·Í·Ç¤ÍºÇ¤Íº TÂ”ial OÂ˜eÂ”Â•ighÂ– Trial oversight is intended to preserve the integrity of the trial by independently verifying a variety of processes and prompting corrective action where necessary. The processes reviewed relate to participant enrolment, consent, eligibility, and allocation to trial groups; adherence to trial interventions and policies to protect participants, including reporting of harms; completeness,"
57,page_57,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ï´ of Ï²Ï´ accuracy and timeliness of data collection; and will verify adherence to applicable policies detailed in the Compliance section of the protocol. In multiÍ²centre trials oversight is considered and described both overall and for each recruiting centre by exploring the trial dataset or performing site visits as described in the trial monitoring plan. Í·Ç¤Í³Í³Ç¤Í¶Ç¤Í¶Ç¤Í³ Clinical Management Team A Clinical Management Team Í¾CMTÍ¿ will be set up to assist with developing the design, coÍ²ordination and strategic management of the trial. The membership, frequency of meetings, activity Í¾including study conduct and data reviewÍ¿ and authority will be covered in a CMT terms of reference. Í·Ç¤Í³Í³Ç¤Í¶Ç¤Í¶Ç¤Í´ SafetÂ› Data Monitoring Committee The Safety Data Monitoring Committee Í¾SDMCÍ¿ is responsible for safeguarding the interests of trial participants, monitoring the accumulating data and making recommendations to on whether the trial should continue as planned. The membership, frequency of meetings, activity Í¾including review of trial conduct and dataÍ¿ and authority will be covered in the SDMC charter. Í¸ EÂ–hicÂ• aÂd DiÂ•Â•eÂiÂaÂ–iÂ‘Â Í¸Ç¤Í³ ReÂ•eaÂ”ch EÂ–hicÂ• AÂ’Â’Â”Â‘Â˜aÂ Before initiation of the trial at any clinical site, the protocol, all informed consent forms and any material to be given to the prospective participant will be submitted to the Health Research Authority Í¾HRAÍ¿ for approval. Any subsequent amendments to these documents will be submitted for further approval. The rights of the participant to refuse to participate in the trial without giving a reason must be respected. After the participant has entered the trial, the clinician remains free to give alternative treatment to that specified in the protocol, at any stage, if the clinician feels it to be in the best interest of the participant. The reasons for doing so must be recorded. However, the participant remains free to change their mind at any time about the protocol treatment and followÍ²up without giving a reason and without prejudicing their further treatment. Í¸Ç¤Í´ RegÂ—ÂaÂ–Â‘Â”Â› AÂ—Â–hÂ‘Â”iÂ–Â› AÂ’Â’Â”Â‘Â˜aÂÂ• This protocol will be submitted to the national competent or equivalent authority Í¾i.e. MHRA in the UK and Food and Drug Administration Í¾FDAÍ¿ in the USÍ¿. This is a Clinical Trial of an Investigational Medicinal Product Í¾IMPÍ¿ as defined by the EU Directive Ï®Ï¬Ï¬Ï­Í¬Ï®Ï¬Í¬EC. Therefore, a Clinical Trial Application is required in the UK. This is a Clinical Trial of an Investigational New Drug as defined by Ï®Ï­CFR Part Ï¯Ï­Ï® of the Code of Federal Regulations. Therefore, an Investigational New Drug Application Í¾INDÍ¿ is required in the US. This trial is a human gene transfer study and therefore in the US must be reviewed by the initial siteÎ–s Institutional Biosafety Committee and possibly by the Recombinant DNA Advisory Committee Í¾RACÍ¿ of the NIHÎ–s Office of Biotechnology Activities Í¾OBAÍ¿."
58,page_58,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï±Ïµ of Ï²Ï´ The progress of the trial, safety issues and reports, including expedited reporting of SUSARs, will be reported to the Competent Authority, regulatory agency or equivalent in accordance with relevant national and local requirements and practices. Í¸Ç¤Íµ OÂ–heÂ” aÂ’Â’Â”Â‘Â˜aÂÂ• The protocol will be submitted by those delegated to do so to the local departments of each participating sites. A copy of the local approval letter Í¾or other relevant approval as aboveÍ¿ and of the Participant Information Sheet Í¾PISÍ¿ and consent form on local headed paper must be forwarded to MeiraGTx UK II Ltd. as part of the site initiation process prior to the site being designated â€˜open to recruitmentâ€™ status. Participating sites receiving funding or support from the US government will obtain a Federal Wide Assurance Í¾FWAÍ¿. For ATIMP trials using Genetically Modified Organisms, organisations should also receive approval from their relevant national body to use the product Í¾i.e. notification to the HSE in the UKÍ¿. Í¸Ç¤Í¶ PÂ”Â‘Â–Â‘cÂ‘Â AÂeÂdÂeÂÂ–Â• MeiraGTx UK II Ltd. will be responsible for amendments to the protocol. MeiraGTx UK II Ltd. will be responsible for ensuring that protocol amendments are submitted to national competent authorities, and to investigators at each clinical trial site. Investigators at each clinical site will be responsible for submitting protocol amendments to the relevant RECÍ¬IRBs for approval, as well as any additional competent authorities in each country that require notification Í¾e.g. the NIH OBAÍ¿. Í¸Ç¤Í· CÂ‘ÂÂ•eÂÂ– Â‘Â” AÂ•Â•eÂÂ– The parents of potential participants will be provided with a Participant Information Sheet Í¾PISÍ¿ and given time to read it fully. Following a discussion with a medically qualified investigator or suitable trained and authorised delegate, any questions will be satisfactorily answered and if the parent is willing for their child to participate, written informed consent will be obtained. During the consent process it will be made completely and unambiguously clear that the parent or guardian of a child is free to refuse to participate in all or any aspect of the trial, at any time and for any reason, without incurring any penalty or affecting the treatment of their child. Children who are unable to consent for themselves will not be enrolled in the trial without the consent of their parentÍ¾sÍ¿ or legal guardianÍ¾sÍ¿. Children or adolescents Í¾aged Ï­Ï­Í²Ï­Ï±Í¿ will be asked to assent or agree. A Participant Information and Assent sheet that describes the details of the trial, trial procedures, and risks in simplified form will be provided to children who have the capacity to provide informed assent. Participation must be refused in the event that assent is not given. Assent forms do not substitute for the consent form signed by the participantâ€™s legally authorized representative. If a child becomes an adult during their participation in the trial, the child will be reconsented as an adult at the time of their next scheduled visit. Consent will be reÍ²sought if new information becomes available that affects the participantâ€™s consent in any way. This will be documented in a revision to the participant information sheet and the"
59,page_59,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²0 of Ï²Ï´ participant legally authorised representative will be asked to sign an updated consent form and assent will be sought as appropriate. These will be approved by the appropriate ethics committee prior to their use. Consent will also be reÍ²sought in the event that a childâ€™s carer changes and when the child reaches the age of Ï­Ï². A copy of the approved consent and assent form are available from the MeiraGTx UK II Ltd. trial team. Í¸Ç¤Í¸ CÂ‘ÂfideÂÂ–iaÂiÂ–Â› All data will be handled in accordance with the General Data Protection Regulation Ï®Ï¬Ï­Ï²Í¬Ï²Ï³Ïµ andÍ¬or the Health Insurance Portability and Accountability Act of Ï­ÏµÏµÏ² Í¾HIPAAÍ¿. These regulations require a signed participant authorization informing the participants of the following: Í» What protected health information Í¾PHIÍ¿ will be collected from participants in this trial Í» Who will have access to that information and why Í» Who will use or disclose that information Í» The rights of a research participant to revoke their authorization for use of their PHI. x Where data will be heldÍ¬stored x Rights that do not apply for research x How and why data is being used In the event that a participant revokes authorization to collect or use PHI, the investigator, by regulation, retains the ability to use all information collected prior to the revocation of participant authorization. For participants that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least vital status Í¾i.e. that the participant is aliveÍ¿ at the end of their scheduled trial period. Participant confidentiality will be held strictly in trust by the investigators, trial staff, and the sponsor and their agents, to the extent provided by Federal, state, and local law. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to any trial information relating to participants. All laboratory specimens, evaluation forms, reports, and other records that leave the site will be identified only by a coded number in order to maintain participant confidentiality. All records will be kept locked and all computer entry and networking programs will use coded numbers only. Participants will not be identified in any publicly released reports of this trial. Access to trial records will be limited to the minimum number of individuals necessary for quality control, audit and analysis. Clinical information will not be released without written permission of the participant, except as necessary for trialÍ²related monitoring, audits, RECÍ¬IRB review, and regulatory inspections by government entities. In these cases, the clinical trial site will provide direct access to all source data, documents, and records maintained by the investigator, including but not limited to, medical records Í¾office, clinic, or hospitalÍ¿ for the trial participants. Trial participants will be informed of this during the informed consent process. No information concerning the trial, or the data will be released to any unauthorized third party without prior written approval of MeiraGTx UK II Ltd."
60,page_60,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²1 of Ï²Ï´ The Case Report Forms Í¾eCRFsÍ¿ will not bear the participantâ€™s name or other personal identifiable data. The participantâ€™s date of birth and trial identificationÍ¬participant number will be used for identification. For other information regarding Data Management please see Section Ï±.Ï­Ï¬.Ï®. Í¸Ç¤Í¹ DecÂaÂ”aÂ–iÂ‘Â Â‘f IÂÂ–eÂ”eÂ•Â–Â• The trial is funded by MeiraGTx UK II Ltd. declares ownership of minority shareholdings in MeiraGTx UK II Ltd. and receipt of payment from MeiraGTx UK II Ltd. for consultancy services. declares ownership of minority shareholdings in MeiraGTx UK II Ltd. and receipt of payment from MeiraGTx UK II Ltd. for consultancy services. Í¸Ç¤Íº IÂdeÂÂiÂ–Â› MeiraGTx UK II Ltd. holds insurance to cover participants for injury caused by their participation in the clinical trial. Participants may be able to claim compensation if they can prove that MeiraGTx UK II Ltd. has been negligent. However, as this clinical trial is being carried out in a hospital, the hospital continues to have a duty of care to the participant in the clinical trial. MeiraGTx UK II Ltd. does not accept liability for any breach in the hospitalâ€™s duty of care, or any negligence on the part of hospital employees. This does not affect the participantâ€™s right to seek compensation via the nonÍ²negligence route. Participants may also be able to claim compensation for injury caused by participation in this clinical trial without the need to prove negligence on the part of MeiraGTx UK II Ltd. or another party. Participants who sustain injury and wish to make a claim for compensation should do so in writing in the first instance to the Chief Investigator, who will pass the claim to MeiraGTx UK II Ltdâ€˜s. insurers. Hospitals selected to participate in this clinical trial shall provide clinical negligence insurance cover for harm caused by their employees and a copy of the relevant insurance policy or summary shall be provided to MeiraGTx UK II Ltd. upon request. Í¸Ç¤Í» FiÂaÂce The trial is fully funded by MeiraGTx UK II Ltd. It is not expected that any further external funding will be sought. Í¸Ç¤Í³Í² AÂ”chiÂ˜iÂg Í¸Ç¤Í³Í²Ç¤Í³ AÂ”chiÂ˜iÂg Â‘f EÂ•Â•eÂÂ–iaÂ TÂ”iaÂ DÂ‘cÂ—ÂeÂÂ–aÂ–iÂ‘Â Requirements for a traceability system and document archiving will be met in line with Regulation Ï­Ï¯ÏµÏ°Í¬Ï®Ï¬Ï¬Ï³ on Advanced Medicinal Products and the applicable Directives therein. To comply with the regulatory requirements, each responsible party Í¾the sponsor of the trial, the manufacturer and the investigatorÍ¾sÍ¿Í¬institutionÍ¾sÍ¿ where the ATIMP is usedÍ¿ will ensure that the information relating to the traceability and accountability, from the production of ATIMPs to the recipient Í¾participantÍ¿ receiving the ATIMPs, are archived for a minimum of Ï¯Ï¬ years after the expiry date of the ATIMP. These requirements will be set out in contractual agreements between the parties and the sponsor."
61,page_61,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²2 of Ï²Ï´ The following essential documentsÍ¬traceability data will be retained by the investigator and institution responsible for the human application of the ATIMP: x Shipping Records for the ATIMP x Certificate of Analysis of the ATIMP x Participant identification code list x ATIMP accountability at the site including final disposition of both used and unused product These records contain relevant information for traceability purposes and at least the following minimum data set from these records should be kept for Ï¯Ï¬ years after the expiry date of the product, or longer if required by the terms of the clinical trial authorisation or by the agreement with the sponsor: x Identification of the investigatorÍ¬institution x Identification of the sponsor x Identification of the manufacturing site x Product nameÍ¬code x Pharmaceutical form, route of administration, quantity of dosage units and strength x Batch number x Trial reference code x Trial participant code x Participant identification code list Í¾links name of recipient to the trial participant codeÍ¿ x Product expiryÍ¬retest date x Date of administration x Participant medical record should also contain the product nameÍ¬code, the trial reference code, trial participant code and administration dates and doses x Records of any product that was unused or destroyed at site and its final status Í¸Ç¤Í³Í³ AcceÂ•Â• Â–Â‘ DaÂ–a The investigatorsÍ¬ institutions will permit trialÍ²related monitoring, audits, REC review, and regulatory inspections, providing direct access to source dataÍ¬documents. Trial participants are informed of this during the informed consent discussion. Participants will consent to provide access to their medical notes. Requests for access to trial data will be considered, and approved in writing where appropriate, after formal application to MeiraGTx UK II Ltd. Í¸Ç¤Í³Í´ AÂciÂÂaÂ”Â› aÂd PÂ‘Â•Â–Ç¦Â–Â”iaÂ CaÂ”e Participants will be invited to participate in a followÍ²up study after completion of this trial. Í¸Ç¤Í³Íµ PÂ—bÂicaÂ–iÂ‘Â PÂ‘ÂicÂ› Í¸Ç¤Í³ÍµÇ¤Í³ TÂ”iaÂ ReÂ•Â—ÂÂ–Â• All proposed scientific publications will be discussed with and approved by the MeiraGTx UK II Ltd. prior to publication. Since this is an exploratory, openÍ²label, Phase IÍ¬II trial, progress and significant findings may be presented at scientific forumsÍ¬meetings andÍ¬or published during the course of the trial. Where the presenter is not a MeiraGTx UK II Ltd. Representative, permission must be sought from MeiraGTx UK II Ltd. The results of the trial will be disseminated regardless of the direction of effect."
62,page_62,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²3 of Ï²Ï´ Í¹ AÂciÂÂaÂ”Â› SÂ–Â—dieÂ• There are no currently planned ancillary studies. Any future ancillary studies will be subject to separate funding and will be submitted for ethical and regulatory review as appropriate. Íº AÂ’Â’eÂdiÂšÇ£ GÂ—idaÂce Â‘Â SÂ–Â—dÂ› CÂ‘ÂdÂ—cÂ– dÂ—Â”iÂg Â–he COVIDÇ¦Í³Í» PaÂdeÂic This Appendix is intended for all ongoing studies at sites worldwide impacted by COVIDÍ²Ï­Ïµ. The measures outlined in this Appendix are temporary, while access to sites is restricted. As restrictions are lifted, the decision to revert back to the protocol in effect prior to the pandemic should be discussed and agreed with the sponsor. It is recognised that the Coronavirus Disease Ï®Ï¬Ï­Ïµ Í¾COVIDÍ²Ï­ÏµÍ¿ pandemic may have an impact on the conduct of this clinical study due to, for example, selfÍ²isolationÍ¬quarantine by participants and studyÍ²site personnel; travel restrictionsÍ¬limited access to public places, including hospitals; study site personnel being reassigned to critical tasks. In alignment with recent health authority guidance, the sponsor is providing options for study related participant management in the event of disruption to the conduct of the study. This guidance does not supersede any local or government requirements or the clinical judgement of the investigator to protect the health and wellÍ²being of participants and site staff. If at any time a participantâ€™s safety is considered to be at risk, study intervention will be discontinued, and study followÍ²up will be conducted. Scheduled visits that cannot be conducted in person at the study site will be performed remotelyÍ¬virtually or delayed until such time that onÍ²site visits can be resumed. At each contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments should be performed if required and as feasible. Participants will also be questioned regarding general health status to fulfil any physical examination requirement. If visits should be delayed past the visit window as per the schedule of events every effort should be made to see this patient as soon as it is deemed safe to do so whether this is due to the countriesâ€™ Governing bodies restrictions being uplifted or under the advice of the CI of that site and patientâ€™s should not be made to wait until the next protocol visit. Every effort should be made to adhere to protocolÍ²specified assessments for participants on study intervention, including follow up. Modifications to protocolÍ²required assessments may be permitted after consultation between the participant and investigator, and with the agreement of the sponsor. Missed assessmentsÍ¬visits will be captured in the eCRF for protocol deviations and should be titled â€˜COVIDÍ²Ï­Ïµ relatedâ€™. Discontinuations of study interventions and withdrawal from the study should be documented with the prefix â€œCOVIDÍ²Ï­ÏµÍ²relatedâ€ in the case report form Í¾CRFÍ¿. The sponsor will continue to monitor the conduct and progress of the clinical study and any changes Í¾eg, delay or discontinuation in recruitment, site monitoring and auditsÍ¿ will be communicated to the sites and health authorities according to local guidance. If a participant has tested positive for COVIDÍ² Ï­Ïµ, the investigator should contact the sponsorâ€™s responsible medical officer to discuss plans for study intervention and followÍ²up. Modifications made to the study conduct as a result of the COVIDÍ²Ï­Ïµ pandemic should be summarised in the clinical study report."
63,page_63,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²Ï° of Ï²Ï´ GUIDANCE SPECIFIC TO THIS PROTOCOL Each patient will be risk assessed on a case by case basis by the PI and hisÍ¬her research team to decide the appropriate care for the patient. Item no Item Management of Item Ï­ Missed assessments Missed assessments will be captured in the EDC system as a deviation with the prefix COVID Ï­Ïµ RELATED. Ï® Protocol Deviations Any deviations to the study protocol due to COVID Ï­Ïµ pandemic will be captured in the EDC system will be entered with the prefix COVID Ï­Ïµ RELATED. Ï¯ Baseline Assessments Baseline assessments for those patients who have had surgery postponed due to COVID Ï­Ïµ Í² these baseline assessments will be valid up to Ïµ months except for Haematology, Biochemistry and Glucose which will need repeating. Ï° Patients may be unable to attend study visit during visit window. It is acknowledged that this is a global crisis and patients may be put at more risk attending hospital appointments due to route of travel into research facility. If appropriate the sponsor will offer expenses for taxi fares to avoid busy train or bus routes. If scheduled visits cannot be conducted within the visit window the site can schedule an additional visit at the earliest opportunity the patients is able to travel, ensuring no visits are completely missed unless authorised by the sponsor. If patients are unable to reach their research facility but are able to seek help at a local ophthalmologist for urgent concerns this is acceptable, and the sponsor will encourage patients to show any nonÍ²trial staff conducting assessments the contact details for the trial staff so that conversations can be had between the trial and nonÍ²trial medical staff Ï² Patients visits conducted outside of visit window Patients will be assessed individually by the sites on a case by case basis and phone interviews may be conducted by sites for all follow up visits up until at least Ï¯ months postÍ²surgery until onÍ²site visits are possible. Patients undergoing telephone assessment will be asked to provide information on any adverse events or other safety concerns. Ï³ Patients selfÍ²quarantined or government implemented quarantine. If patients andÍ¬or their caregiver are under quarantine and unable to leave home, their cases will be assessed by medical monitors and PI as to risk of delayed appointment. Í¾e.g"
64,page_64,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²Ï± of Ï²Ï´ ongoing AEs, date of last appointment, less than Ï¯ months since interventionÍ¿. Ï´ Potential lack of reporting of symptoms due to delayed visits Delayed reporting of SAEs, SARs Î˜ SUSARsÍ² Potential for events to not be reported within Ï®Ï° hours of occurrence Delayed Participant reporting of Adverse Events All participants are provided with emergency cards on enrolment to the study to enable Ï®Ï°Í²hour contact with study investigators. All events should be reported by an Investigator Í¾as assigned on the delegation logÍ¿ or another member of the site team, in the Investigators absence and where delegated, within Ï®Ï° hours of the investigatorÍ¬site being made aware. Sites have been advised how to still maintain timelines for reporting if impeded by pandemic restrictions. Ïµ Emergencies during the study and the provision of emergency contact arrangements: If the participants facing difficulties in contacting the Trial Team in the event of emergencies, they have been provided with an alert card to inform other healthcare providers of their participation in the gene therapy trial. The Trial card includes the Ï®Ï°Í¬Ï³Í²hour contact number, patients trial code, trial number, brief details of the trial intervention and EudraCT number. Ï­Ï¬ Patients may require NIMPs that they would have collected a scheduled study visit. Site research staff will be in regular contact with their study patients and should they require NIMPs, the site pharmacy will be able to courier them to the patient and charge the cost to the sponsor. Ï­Ï­ Assessment results outside of window not true representation of protocol stated timepoints Patient safety will be most important factor to consider. Patients will be invited as close to visit window as possible and deviations recorded where applicable. Ï­Ï® Questionnaire responses could be incorrect due to expected visit vs actual visit attended. Patient may confuse true answers if questionnaire asks for certain timepoints. Site research staff will explain questionnaire details before patient answers. Ï­Ï¯ ClinicianÍ¬s and site research staff unavailable due to contraction of virus Site to ensure appropriate staff are available and documented on the delegation log to provide medical cover if the PI is unavailable. Ï­Ï° Monitor may not be allowed on site or may be quarantined and unable to visit. Monitors will be encouraged to attend site where possible, if unable will conduct remote monitoring as much as possible and arrange as many visits as is required to get back on track once site reÍ²opens."
65,page_65,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²Ï² of Ï²Ï´ Í» PÂ”Â‘Â–Â‘cÂ‘Â AÂeÂdÂeÂÂ–Â• Protocol Version and Date Reason for Amendment Protocol vÏ­.Ï¬ Ï­Ï²NovÏ®Ï¬Ï­Ï´ Initial version Protocol vÏ®.Ï¬ Ï®ÏµJanÏ®Ï¬Ï­Ïµ Reduction of assessments based on analysis of CNGBÏ¯ MGTÏ¬Ï¬Ï² data to reduce assessment burden on participants and clinical sites and addition of optional MRI assessment. Protocol vÏ¯.Ï¬ Update to contraception wording on request of MHRA Protocol vÏ°.Ï¬ Change of baselineÍ¬screening window prior to surgery from Ï² months to Ïµ months. Addition of Photoaversion Device Questionnaires. Removal of MRI assessment Protocol vÏ±.Ï¬ Updated steroid Î˜ surgical risks, and local steroid use detailed. Guidance included on the management of patients during COVIDÍ²Ï­Ïµ pandemic Further details added to exclusion criteria. ReÍ²illustration of dose escalation table Í¾no changes madeÍ¿ Protocol vÏ².Ï¬ Removed dose expansion cohort Í¾as this will now take part as a separate Phase ll interventional studyÍ¿ Included details on additional adult cohort taking place in the US. Corrected inconsistencies"
66,page_66,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²Ï³ of Ï²Ï´ Í³Í² RefeÂ”eÂceÂ• Aboshiha J, Dubis AM, Carroll J, et al. The cone dysfunction syndromes. Br J Ophthalmol Ï®Ï¬Ï­Ï²;Ï­Ï¬Ï¬Í¾Ï­Í¿:Ï­Ï­Ï±Í´Ï­Ï®Ï­. Annear,M.J., Bartoe,J.T., Barker,S.E., Smith,A.J., Curran,P.G., Bainbridge,J.W., Ali,R.R., and PetersenÍ²Jones,S.M. Í¾Ï®Ï¬Ï­Ï­Í¿. Gene therapy in the second eye of RPEÏ²Ï±Í²deficient dogs improves retinal function. Gene Ther. Ï­Ï´, Ï±Ï¯Í²Ï²Ï­. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, Viswanathan A, Holder GE, Stockman A, Tyler N, PetersenÍ²Jones S, Bhattacharya SS, Thrasher AJ, Fitzke FW, Carter BJ, Rubin GS, Moore AT, Ali RR. Effect of gene therapy on visual function in LeberÎ–s congenital amaurosis. N Engl J Med, Ï®Ï¬Ï¬Ï´, Ï¯Ï±Ï´:Ï®Ï®Ï¯Ï­Í²Ïµ Bainbridge JW, Mehat MS, Sundaram V, Robbie SJ, Barker SE, Ripamonti C, Georgiadis A, Mowat FM, Beattie SG, Gardner PJ, Feathers KL, Luong VA, Yzer S, Balaggan K, Viswanathan A, de Ravel TJL, Casteels I, Holder GE, Tyler N, Fitzke FW, Weleber RG, Nardini M, Moore AT, Thompson DA, PetersenÍ²Jones SM, Michaelides M, van den Born LI, Stockman A, Smith AJ, Rubin G and Ali RR. LongÍ²term effect of gene therapy on Leber Congenital amaurosis. N Eng J Med, Ï®Ï¬Ï­Ï±, Ï¯Ï³Ï®: Ï­Ï´Ï´Ï³Í²ÏµÏ³. Balaggan KS, Duran Y, Georgiadis A, et al. Absence of ocular malignant transformation after subÍ²retinal delivery of rAAVÏ®Í¬Ï® or integrating lentiviral vectors in pÏ±Ï¯Í²deficient mice. Gene therapy Ï®Ï¬Ï­Ï®;Ï­ÏµÍ¾Ï®Í¿:Ï­Ï´Ï®Ï­Ï´Ï´. Chan AW, Tetzlaff JM, Altman DG et Al. SPIRIT Ï®Ï¬Ï­Ï¯ Statement: Defining Protocol Items for Clinical Trials. Ann Intern Med Ï®Ï¬Ï­Ï¯; Ï­Ï±Ï´:Ï®Ï¬Ï¬Í²Ï®Ï¬Ï³. Chan AW, Tetzlaff, Gotzsche et Al. SPIRIT Ï®Ï¬Ï­Ï¯ explanation and elaboration: guidance for protocols of clinical trials. BMJ Ï®Ï¬Ï­Ï¯; Ï¯Ï°Ï²: eÏ³Ï±Ï´Ï². Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, Pang JJ, Sumaroka A, Windsor EA, Wilson JM, Flotte TR, Fishman GA, Heon E, Stone EM, Byrne BJ, Jacobson SG, Hauswirth WW. Human gene therapy for RPEÏ²Ï± isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A, Ï®Ï¬Ï¬Ï´.Ï­Ï¬Ï±:Ï­Ï±Ï­Ï­Ï®Í²Ï³. Cideciyan AV, Jacobson SG, Beltran WA, Sumaroka A, Swider M, Iwabe S, Roman AJ, Olivares MB, Schwartz SB, KomÃ¡romy AM, Hauswirth WW, Aguirre GD. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A, Ï®Ï¬Ï­Ï¯, Ï­Ï­Ï¬Í¾Ï²Í¿:EÏ±Ï­Ï³Í²Ï®Ï±. Daya S and Berns KI. Gene therapy using AdenoÍ²associated virus vectors. Clin Microbiol Rev Ï®Ï¬Ï¬Ï´;Ï®Ï­Í¾Ï°Í¿:Ï±Ï´Ï¯Í´Ï±ÏµÏ¯. Kohl. S, Jagle. H, and Wissinger. B, Ï®Ï¬Ï­Ï¯, AchromatopsiaÍ• GeneReviewsÎ  Í² NCBI Bookshelf: National Institute of Health Russell SR, Bennett J, High KA, et al. Phase III trial of AAVÏ®Í²hRPEÏ²Ï±vÏ® Í¾SPKÍ²RPEÏ²Ï±Í¿ to treat RPEÏ²Ï±Í²mediated inherited retinal dystrophies Í¾IRDsÍ¿: topÍ²line safety and efficacy results. Presented at the Retina Society Annual Scientific Meeting, Paris, Ï­Ï¬ October Ï®Ï¬Ï­Ï±."
67,page_67,"CNGAÏ¯CNGAÏ¯ Gene Therapy trial for Achromatopsia CNGAÏ¯ MGTÏ¬Ï­Ï® Protocol version Ï².Ï¬ Ï­Ï²AprÏ®Ï¬Ï®Ï­ P a g e Ï²Ï´ of Ï²Ï´ Russell SR, Bennett J, Wellmann JA, et al. Efficacy and safety of voretigene neparvovec Í¾AAVÏ®Í²hRPEÏ²Ï±vÏ®Í¿ in patients with RPEÏ²Ï±Í²mediated inherited retinal dystrophy: a randomised, controlled, openÍ²label, phase Ï¯ trial. The Lancet Ï®Ï¬Ï­Ï³;Ï¯ÏµÏ¬Í¾Ï­Ï¬Ï¬ÏµÏ³Í¿:Ï´Ï°ÏµÍ´Ï´Ï²Ï¬. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of Uveitis Nomenclature Í¾SUNÍ¿ Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol, Ï®Ï¬Ï¬Ï±, Ï­Ï°Ï¬:Ï±Ï¬ÏµÍ´Ï±Ï­Ï². Judd DB. Facts of colorÍ²blindness. J Opt Soc Amer Ï­ÏµÏ°Ï¯;Ï¯Ï¯:Ï®ÏµÏ°Í´Ï¯Ï¬Ï³ Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, Banfi S, Marshall KA, Testa F, Surace EM, Rossi S, Lyubarsky A, Arruda VR, Konkle B, Stone E, Sun J, Jacobs J, DellÎ–Osso L, Hertle R, Ma JX, Redmond TM, Zhu X, Hauck B, Zelenaia O, Shindler KS, Maguire MG, Wright JF, Volpe NJ, McDonnell JW, Auricchio A, High KA, Bennett J. Safety and efficacy of gene transfer for LeberÎ–s congenital amaurosis. N Engl J Med, Ï®Ï¬Ï¬Ï´, Ï¯Ï±Ï´:Ï®Ï®Ï°Ï¬Í²Ï´. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA. Nat Med, Ï®Ï¬Ï¬Ï², Ï­Ï®:Ï¯Ï°Ï®Í²Ï³ Michaelides M, Hunt DM, and Moore AT. The cone dysfunction syndromes. Br J Ophthalmol Ï®Ï¬Ï¬Ï°;Ï´Ï´Í¾Ï®Í¿:Ï®ÏµÏ­Í´Ï®ÏµÏ³. Natkunarajah M, Trittibach P, McIntosh J, Duran Y, Barker SE, Smith AJ, Nathwani AC, Ali RR. Assessment of ocular transduction using singleÍ²stranded and selfÍ²complementary recombinant adenoÍ²associated virus serotype Ï®Í¬Ï´. Gene Ther, Ï®Ï¬Ï¬Ï´, Ï­Ï±:Ï°Ï²Ï¯Í²Ï³. Nowrouzi A, PenaudÍ²Budloo M, Kaeppel C, Appelt U, Le Guiner C, Moullier P, Kalle CV, Snyder RO, Schmidt M. Integration Frequency and Intermolecular Recombination of rAAV Vectors in NonÍ²human Primate Skeletal Muscle and Liver. Mol Ther, Ï®Ï¬Ï­Ï®, Ï®Ï¬Í¾Ï²Í¿:Ï­Ï­Ï³Ï³Í²Ï´Ï². Sharpe LT and Nordby K. Total colourÍ²blindness: an introduction. In: Night Vision: Basic, Clinical and Applied Aspects. R. F. Hess, L. T. Sharpe and K. Nordby. Cambridge, Cambridge University Press Ï­ÏµÏµÏ¬:Ï®Ï±Ï¯Í´Ï®Ï´Ïµ. Sharpe LT, Stockman A, JÃ¤gle H, et al. Opsin genes, cone photopigments, color vision, and color blindness. In: Color Vision: from Genes to Perception. KR Gegenfurtner and Sharpe LT Í¾EdsÍ¿. Cambridge University Press Ï­ÏµÏµÏµ:Ï­Í´Ï±Ï­. Stieger K, Colle MA, Dubreil L, MendesÍ²Madeira A, Weber M, Le Meur G, Deschamps JY, Provost N, Nivard D, Cherel Y, Moullier P, Rolling F. Subretinal delivery of recombinant AAV serotype Ï´ vector in dogs results in gene transfer to neurons in the brain. Mol Ther, Ï®Ï¬Ï¬Ï´,Ï­Ï²:ÏµÏ­Ï²Í²Ï®Ï¯. Vandenberghe LH, Bell P, Maguire AM, et alÍ˜ AAVÏµ targets cone photoreceptors in the nonhuman primate retina. PLoS One Ï®Ï¬Ï­Ï¯;Ï´:eÏ±Ï¯Ï°Ï²Ï¯. Vandenberghe LH, Bell P, Maguire AM, et alÍ˜ Dosage thresholds for AAVÏ® and AAVÏ´ photoreceptor gene therapy in monkey. Sci Transl Med Ï®Ï¬Ï­Ï­;Ï¯:Ï´Ï´raÏ±Ï°."
